pharmadots-adc-connect1000true0006R.pdf2025-08-12T09:14:02.000Z"755e2829180a2064f6764d5e09c02943"CRC64NVMEFULL_OBJECT1941299STANDARD01-07-2025/2025-07-01T13:56:08.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-07-2025/Anwita Biosciences.JPG2025-07-01T13:56:08.000Z"bf98f2147eb1e4365236b5004c2aaf1b"CRC64NVMEFULL_OBJECT61543d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-07-2025/Biotheus.JPG2025-07-01T13:56:08.000Z"1c80660b3004a322b91726fc5e36ab6c"CRC64NVMEFULL_OBJECT60698d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-07-2025/Harvard Medical School.JPG2025-07-01T13:56:08.000Z"9d5804c19510a16be8f90c65aa878a5f"CRC64NVMEFULL_OBJECT44150d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-07-2025/ProScan.JPG2025-07-01T13:56:08.000Z"752cd617fd1571cf09e5faf7d0e73b6c"CRC64NVMEFULL_OBJECT46523d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-07-2025/Protheragen.JPG2025-07-01T13:56:08.000Z"86c08582beac3c1e0b22c51329b48285"CRC64NVMEFULL_OBJECT35724d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025 Company logo/2025-08-01T13:33:09.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0STANDARD01-08-2025 Company logo/Antikor.JPG2025-08-01T13:33:09.000Z"6f0d1438112a31735964c849eb5b4a28"CRC64NVMEFULL_OBJECT38693d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025 Company logo/Duke University Medical Center.JPG2025-08-01T13:33:09.000Z"e9482100a7870675f9dfe82d11758a4f"CRC64NVMEFULL_OBJECT41971d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025 Company logo/Gennao Bio.JPG2025-08-01T13:33:09.000Z"a7622bce663475581a0e70ab8787925c"CRC64NVMEFULL_OBJECT42673d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025 Company logo/Keio University School of Medicine.JPG2025-08-01T13:33:09.000Z"ff0c00b4b647684a90037ad97035ab61"CRC64NVMEFULL_OBJECT58329d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025 Company logo/PDX Pharmaceutical.JPG2025-08-01T13:33:09.000Z"ac1559209fa8facaf8b9e894a3abbc51"CRC64NVMEFULL_OBJECT43393d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025 Company logo/University College London.JPG2025-08-01T13:33:09.000Z"d3463a669ab2a39ef046299fad3beca8"CRC64NVMEFULL_OBJECT33262d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/2025-08-01T13:30:51.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0STANDARD01-08-2025/3xGFPp_FGF1E_LPET_MMAE.JPG2025-08-01T06:58:27.000Z"bf10d1192e736fedbae215dd1e583e8e"CRC64NVMEFULL_OBJECT63864d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/ANG1009.JPG2025-08-01T06:58:27.000Z"9c6bf56480b541f4a1e49694d76149f4"CRC64NVMEFULL_OBJECT59478d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/AVA6000.JPG2025-08-01T06:58:27.000Z"e3c4217b9b66e837bbb767c2c8250c1e"CRC64NVMEFULL_OBJECT49537d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/Antikor.JPG2025-08-01T13:30:51.000Z"6f0d1438112a31735964c849eb5b4a28"CRC64NVMEFULL_OBJECT38693STANDARD01-08-2025/BGC0222.JPG2025-08-01T06:58:27.000Z"06541ea20498083dedbbf606aa2ce436"CRC64NVMEFULL_OBJECT57266d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/BT7480.JPG2025-08-01T06:58:27.000Z"5db371c8a9d1b8c983c8e9049b560a44"CRC64NVMEFULL_OBJECT47828d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/DTS108.JPG2025-08-01T06:58:27.000Z"35002d6039f2ef0e4b996b76f3bc7032"CRC64NVMEFULL_OBJECT68068d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/DTS201 sodium.JPG2025-08-01T06:58:27.000Z"49ead2f7042282587b44bad9cb2c82a2"CRC64NVMEFULL_OBJECT41977d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/DTXP7.JPG2025-08-01T06:58:27.000Z"bcc9b4f16096de2b8545c781a733d48e"CRC64NVMEFULL_OBJECT55227d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/DoxpDC.JPG2025-08-01T06:58:27.000Z"aa9dee342bcae0e47efa1a30e67190dd"CRC64NVMEFULL_OBJECT51614d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/Duke University Medical Center.JPG2025-08-01T13:30:51.000Z"e9482100a7870675f9dfe82d11758a4f"CRC64NVMEFULL_OBJECT41971STANDARD01-08-2025/Gennao Bio.JPG2025-08-01T13:30:51.000Z"a7622bce663475581a0e70ab8787925c"CRC64NVMEFULL_OBJECT42673STANDARD01-08-2025/Keio University School of Medicine.JPG2025-08-01T13:30:51.000Z"ff0c00b4b647684a90037ad97035ab61"CRC64NVMEFULL_OBJECT58329STANDARD01-08-2025/Lutathera.JPG2025-08-01T06:58:27.000Z"edf9b686dcb86790591b9eeb824546f1"CRC64NVMEFULL_OBJECT67751d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/MMAEAffibodyHER2SA4A.JPG2025-08-01T06:58:27.000Z"1eda391ace09bd5696345fb31bc2e8eb"CRC64NVMEFULL_OBJECT64505d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/MMAEFGF1ESA4A.JPG2025-08-01T06:58:27.000Z"25b5e7b84447057f07b60347813ff78a"CRC64NVMEFULL_OBJECT62968d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/MMAEFGF2vSA4A.JPG2025-08-01T06:58:27.000Z"8b035747f86dc3fc43589ddfd446a1ac"CRC64NVMEFULL_OBJECT62659d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/PDX Pharmaceutical.JPG2025-08-01T13:30:51.000Z"ac1559209fa8facaf8b9e894a3abbc51"CRC64NVMEFULL_OBJECT43393STANDARD01-08-2025/PhAcALGPDox .JPG2025-08-01T06:58:27.000Z"6d8d32f57532cfea9677fc9107133aa2"CRC64NVMEFULL_OBJECT45030d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/Pluvicto.JPG2025-08-01T06:58:28.000Z"737412d011496255f38c9b8ba01117a7"CRC64NVMEFULL_OBJECT57888d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/Pt(IV)M13.JPG2025-08-01T06:58:28.000Z"052f35224131eb6f278a6cece66ecdee"CRC64NVMEFULL_OBJECT39635d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/TFcvcMMAE.JPG2025-08-01T06:58:28.000Z"8e9ebf46a792ff1d9f9eb6fb1c75b009"CRC64NVMEFULL_OBJECT73214d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/TOOLBOXDM1.JPG2025-08-01T06:58:28.000Z"83fe74c988137f9fcd96b00ba7b474b6"CRC64NVMEFULL_OBJECT67125d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/University College London.JPG2025-08-01T13:30:51.000Z"d3463a669ab2a39ef046299fad3beca8"CRC64NVMEFULL_OBJECT33262STANDARD01-08-2025/VIP1339.JPG2025-08-01T06:58:28.000Z"0e3a9ee53ddedd24636ad8c828dd5e1c"CRC64NVMEFULL_OBJECT71091d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/VIP280.JPG2025-08-01T06:58:28.000Z"b2fbb6de691f0a7e5d0ce62ed164970c"CRC64NVMEFULL_OBJECT66722d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/VIP550.JPG2025-08-01T06:58:28.000Z"97c81c2d4948d5105e4cc808aa33da42"CRC64NVMEFULL_OBJECT66607d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/ZHER2342 CupidPsyche SiPc.JPG2025-08-01T06:58:28.000Z"3926d44b0aabcd595d996891f7a06a60"CRC64NVMEFULL_OBJECT73616d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/anti-HER2 Fab-SN38.jpg2025-08-01T12:53:55.000Z"d9a991cbdfeb355d517174b301885122"CRC64NVMEFULL_OBJECT62624d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/anti-HER2 scFvSG4015PEGCy5C′ dots.JPG2025-08-01T06:58:27.000Z"72462570d50f88f28ca5fed00b1fdb29"CRC64NVMEFULL_OBJECT40623d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/ePSMA-DM1.jpg2025-08-01T07:55:04.000Z"3100653f1deb7ea143ccdc5700a4183d"CRC64NVMEFULL_OBJECT55632d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD01-08-2025/eSOMADM1.JPG2025-08-01T06:58:27.000Z"c4e894aff4fe9dac54279d82e2d8f70a"CRC64NVMEFULL_OBJECT56694d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/2025-09-02T10:59:33.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0STANDARD02_09_2025/A cytotoxic peptide designed for tumor-targeted delivery of co-injected molecules.jpg2025-09-02T11:32:55.000Z"57c1e489ba915ee21584edcef37ef0c9"CRC64NVMEFULL_OBJECT327223d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/Boehringer Ingelheim.jpg2025-09-03T07:08:59.000Z"2e5dde6775066e1e96b4371c18db0844"CRC64NVMEFULL_OBJECT78140d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/Case Comprehensive Cancer Center.png2026-03-02T12:05:17.000Z"6cc2e39aeee351baf7c5aa5f2b84d956"CRC64NVMEFULL_OBJECT6821d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/Enzon Pharmaceuticals.jpg2025-09-03T08:54:31.000Z"c9ba4cff2edd5cbf5641ba2b7849c61f"CRC64NVMEFULL_OBJECT54163d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/Lisata Therapeutics.jpg2025-09-02T11:55:01.000Z"a292a2fd7f8d59d753250715bb2044f3"CRC64NVMEFULL_OBJECT45833d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/M.D. Anderson Cancer Center.png2026-03-02T10:53:35.000Z"4d8c48c000a1a1e2312f312b171bf530"CRC64NVMEFULL_OBJECT9169d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/Norroy Bioscience.JPG2025-09-02T10:59:33.000Z"7f233fe6174208edecfa9fa99b1e74c1"CRC64NVMEFULL_OBJECT39205d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/Ottimo Pharma.jpg2026-03-02T10:19:45.000Z"52793093b89dfbf72b73ce2a43a96670"CRC64NVMEFULL_OBJECT55391d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/Strategic Alliance.png2026-03-02T10:55:20.000Z"5b901d44d1095eadaf8a51e24cb82e3a"CRC64NVMEFULL_OBJECT10016d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/Theratechnologies.JPG2025-09-02T10:59:33.000Z"16279af07762fa2735efe50270d00d84"CRC64NVMEFULL_OBJECT43222d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/UCSD Moores Cancer Center.JPG2025-09-02T10:59:33.000Z"7bb26cc4d5f201d347b4e4b526e896f1"CRC64NVMEFULL_OBJECT44249d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/iRGD-MMAF...jpg2025-09-02T11:41:47.000Z"676cd0da791d6a40254869d43a63ff79"CRC64NVMEFULL_OBJECT53962STANDARD02_09_2025/iRGD-MMAF.jpg2025-09-02T11:35:34.000Z"cdcf14820a23fbf2b8a052db7acf561a"CRC64NVMEFULL_OBJECT59788d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD02_09_2025/y-mabs therapeutics.jpg2025-09-04T14:29:23.000Z"b45e4a07860a9da031bf1d46f79a29fa"CRC64NVMEFULL_OBJECT45181d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD03-14-23-Mythic_AACR-Poster-Draft_FINAL.pdf2025-05-26T07:30:29.000Z"b9fdcfed258afc0e1f99ba2f3fde4070"CRC64NVMEFULL_OBJECT2489198d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/2025-05-07T13:19:22.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/Crescendo Biologics.png2026-02-19T07:38:18.000Z"cbb5a1aa2922659c060a0ddba5355c46"CRC64NVMEFULL_OBJECT5003d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/Excellamol.jpg2026-02-19T09:28:46.000Z"b307a459262399dcd4edd6e85f8d417b"CRC64NVMEFULL_OBJECT9080d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/LeadsBiolabs.JPG2025-05-07T13:19:22.000Z"dede8d9a378702bd79146ea50b7b0571"CRC64NVMEFULL_OBJECT47106d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/NBE.png2026-02-19T07:18:48.000Z"a7bcb99bd4c2cae1baa1f20a0ce8f933"CRC64NVMEFULL_OBJECT5411d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/Nextpoint.JPG2025-05-07T13:19:22.000Z"aa1fc09e7af72c87ea9794773613380c"CRC64NVMEFULL_OBJECT34766d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/Nordic Nanovector.png2026-02-19T10:03:06.000Z"cb027f733cc27d8958ab3e455dadd6e7"CRC64NVMEFULL_OBJECT3068d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/OXB.L_BIG.png2026-02-25T10:06:26.000Z"97740c00ebc531f7ae3c769fd06a9318"CRC64NVMEFULL_OBJECT38807d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/Orgenesis.png2026-02-19T11:46:28.000Z"38ef25a58e422cfb45fd2a2693820440"CRC64NVMEFULL_OBJECT4805d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/Recourse Biologics.png2026-02-19T12:45:00.000Z"247af182640ffb91599ac3d9c2b57a27"CRC64NVMEFULL_OBJECT5492d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/Shanghai affinity biopharmaceutical.jpg2026-02-19T13:48:33.000Z"a26159fbdfecdd8183747fda9ef25ffc"CRC64NVMEFULL_OBJECT3967d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/University_of_Minnesota.png2026-02-25T10:32:22.000Z"7d7d4f5473de3e8508f09bf6e0d1a416"CRC64NVMEFULL_OBJECT437198d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/University_of_Minnesota.svg2026-02-25T10:30:31.000Z"57af699a4478f3f833b7ad7e79e512e2"CRC64NVMEFULL_OBJECT52850STANDARD07-05-2025/Zhangjiang Biotechnology.png2026-02-19T14:28:37.000Z"8dfa19df7e9afa13b16e853a3e6bbee3"CRC64NVMEFULL_OBJECT9575d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD07-05-2025/blau-farmaceutica.png2026-02-27T05:46:41.000Z"b7b358311ccb683d07459d63a32888f3"CRC64NVMEFULL_OBJECT191771d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-05-2025/2025-05-08T14:10:13.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-05-2025/08-05-2025/2025-05-08T14:12:01.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-05-2025/08-05-2025/Almac Discovery.JPG2025-05-08T14:12:01.000Z"23a80c19f8f9353739e3b762b3e175c7"CRC64NVMEFULL_OBJECT33703d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-05-2025/08-05-2025/Baylink Biosciences (2).JPG2025-05-08T14:12:01.000Z"0f6c3bb5cd28755cfaf2379d124ac4c9"CRC64NVMEFULL_OBJECT43106d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-05-2025/08-05-2025/InduPro Therapeutics.JPG2025-05-08T14:12:01.000Z"68eee92e68393afb3a15ee94349fc920"CRC64NVMEFULL_OBJECT38162d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-05-2025/08-05-2025/Tavotek Biotherapeutics.JPG2025-05-08T14:12:01.000Z"96e00bca94f10b0bb1ca1e11999fee69"CRC64NVMEFULL_OBJECT47042d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-09-2025/2025-09-08T07:09:38.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0STANDARD08-09-2025/Cancer Research Society.jpg2026-02-09T12:36:34.000Z"76e29397ff2f7e3daa2c39e7c44f7c95"CRC64NVMEFULL_OBJECT9068d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-09-2025/Herlev Hospital.jpg2026-02-09T12:32:32.000Z"f2f12d3864f75e3c0d70630b2ecc0c23"CRC64NVMEFULL_OBJECT34523d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-09-2025/JPM Presentation 2026 WEBSITE version.pdf2026-02-26T11:24:00.000Z"b8f423224edca9b7aae711dfaf87da85"CRC64NVMEFULL_OBJECT2330105d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-09-2025/KU Leuven.png2026-02-09T12:28:31.000Z"4dfea916a9ced0c7a3a1e59fe0a49d20"CRC64NVMEFULL_OBJECT4300d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-09-2025/Linyi People's Hospita.png2026-02-09T12:38:41.000Z"9676097847faf777eeaa14e84b4aad6a"CRC64NVMEFULL_OBJECT8063d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-09-2025/National Medical Research Radiological Centre of the Ministry of Health of Russia.jpg2026-02-09T12:24:48.000Z"f7166786b434728bafd54065689f9631"CRC64NVMEFULL_OBJECT13854d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-09-2025/Paclitaxel poliglumex (XYOTAX).jpg2025-09-10T06:17:14.000Z"09e71e799911f50a03dd84fb6b5e60d3"CRC64NVMEFULL_OBJECT54778d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-09-2025/Paclitaxel poliglumex (XYOTAX™, CT-2103).jpg2025-09-10T06:27:30.000Z"bfdc09aa77689a7e222c8b72defe48a1"CRC64NVMEFULL_OBJECT57031d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-09-2025/Shanghai General Hospital.png2026-02-09T12:35:23.000Z"453e440dd9fe527c745dc2ae5e1bf5de"CRC64NVMEFULL_OBJECT9788d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-09-2025/Université de Tours.JPG2025-09-08T07:09:39.000Z"48c2988ed93d36b48e73131ba3f768a5"CRC64NVMEFULL_OBJECT45687d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD08-09-2025/cornell university.JPG2025-09-08T07:09:39.000Z"fd9aa4daa08963368ac40537da1bbe42"CRC64NVMEFULL_OBJECT77378d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1-Cancer Institute and Hospital, Chinese Academy of Medical Sciences.jpg2025-12-30T12:12:04.000Z"1f53da2fffe8d165875dd75a12a7d678"CRC64NVMEFULL_OBJECT119063STANDARD10.3109@10428194.2014.894190.pdf2025-08-14T09:08:54.000Z"0d18dfefa74ddfd2faeb581721668497"CRC64NVMEFULL_OBJECT449338d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1016_Pembrolizumab plus R-CHOP 1L therapy for PMBL with high rates of ctdna negativity interim efficacy analysis_Katharine Lewis.pdf2025-12-19T12:33:03.000Z"f07f750bb79cb2a17f8f761cf3eedb56"CRC64NVMEFULL_OBJECT5201008d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1017_SHR-A1811_Henan Cancer Hospital_BC_REIN_Clinical Results_Yan.pdf2025-06-13T05:24:06.000Z"2008c04a11f94f97288a936f0a09589c"CRC64NVMEFULL_OBJECT7402581d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1019_sac-TMT_Nanjing Medical University_TNBC_Ph2_OptiTROP_Breast05_Clinical Resuts_Yin.pdf2025-06-13T13:36:03.000Z"0028700a3e8f5a0aeaf83c3e7897c8ca-2"CRC64NVMEFULL_OBJECT9326277d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1020_Long-term follow-up with Mosunetuzumab in combination with polatuzumab vedotin_Ghosh.pdf2025-12-19T09:24:49.000Z"051828858fc76e4671eb9e469bd32fbf"CRC64NVMEFULL_OBJECT1998719d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1025eTiP.jpg2025-10-21T12:16:24.000Z"7e9e6a663e075f8208fb96d48597842d"CRC64NVMEFULL_OBJECT7977774d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD103eP_Tislelizumab_Cholangiocarcinoma_Hongli Yu.pdf2025-11-06T13:18:14.000Z"7d8fdce46cbe626c8f246038ab680c88"CRC64NVMEFULL_OBJECT289089d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1053_XMT-2056, a HER2-targeted Immunosynthen STING agonist antibody-drug conjugate,induces anti-tumor activity at low doses in preclinical models_Lowinger.jpg2025-05-26T09:50:06.000Z"b2916bb89c4437b342de852f9cfc57e2-2"CRC64NVMEFULL_OBJECT10183604d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1060P_Adebrelimab_SCC_Interim Analysis of Adebrelimab plus Famitinib as Later-line Treatment for Extensive-Stage_Tong Chen (2).pdf2025-12-18T08:34:23.000Z"376636c10686908ea9ca927b71dfa0b5"CRC64NVMEFULL_OBJECT936626d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1065MO_FRα_AZD5335_Ovarian cancer_First in human study of AZD5335_Oaknin.pdf2025-10-24T09:40:23.000Z"17a0a26071f5ca375ab782722f77a612"CRC64NVMEFULL_OBJECT1687094d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1069P_B7 H4_HS 20089_PROC_Phase 2 study_Wu.pdf2025-10-28T07:34:39.000Z"04778b746ea3a4e408e88640cc056828"CRC64NVMEFULL_OBJECT482060d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD106_SHR1826_Sun Yat sen University Cancer Center_Solid Tumor_Ph I_Clinical results_Zhang.pdf2025-06-20T07:04:17.000Z"b087d598d9bfa5d1bbf795b80b63a02d-3"CRC64NVMEFULL_OBJECT19473360d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1074eP.pdf2025-12-12T12:39:07.000Z"55599fe988a5f186fa50506815278319"CRC64NVMEFULL_OBJECT99766d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD107_SHRA2102_Shanghai Jiao Tong University School of Medicine_Solid Tumor_Ph I_Clinical results_Zhong.pdf2025-06-13T12:27:25.000Z"18ac9603c837def16039bdad42f331aa-2"CRC64NVMEFULL_OBJECT9161164d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1103_SHR-A1811 plus adebrelimab in unresectable or metastatic triple-negative breast cancer results from a phase 1b 2 expansion cohort_Liang.jpeg2025-06-13T11:02:06.000Z"85916f2aabdc2e7a0aebf97aea0798ad"CRC64NVMEFULL_OBJECT3210232d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1109_RC48_ADC_RemeGen_TNBC_Efficacy and safety of RC48_ADC in TNBC subtypes_FUSCC_TNBC_umbrella trial results_Liu.jpeg2025-06-12T19:51:32.000Z"f788c0617b35e4bfa76b00c38d8b1d9e"CRC64NVMEFULL_OBJECT3406629d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1111P_TROP2_sac-TMT_amEC_MK-2870 001 result_Wang.pdf2025-10-23T13:36:00.000Z"3a6bb273389b99cde9b030bfa09d5647"CRC64NVMEFULL_OBJECT690735d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1113P_Dostarlimab_EC_Bradley James Monk.pdf2025-11-05T14:03:47.000Z"515a3a037dde89410b631da53a3fa777"CRC64NVMEFULL_OBJECT864514d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1121P_FRα_Rina S_arEC_cohort B2 of RAINFOL™ 01 study_Cloven.pdf2025-10-23T14:12:40.000Z"c43bf0eb0e61f583b135d6794ee82c24"CRC64NVMEFULL_OBJECT910044d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1124P_Pembrolizumab_Endometrial_Christian Marth.pdf2025-10-30T09:09:21.000Z"386d19ab3c1555db84a3e4bdfc23b389"CRC64NVMEFULL_OBJECT454607d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1160P_Pembrolizumab_Melanoma_Vibostolimab Coformulated With Pembrolizumab_KEYVIBE-010_Chen.pdf2025-12-18T09:23:21.000Z"41effa204be51a5244de87d4911e4204"CRC64NVMEFULL_OBJECT298574d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1168P_TROP2_sac-TMT_amCervical Cancer_MK 2870 001 trial result_Wang.pdf2025-10-23T14:01:02.000Z"43760706af16599aefbc2debb370221b"CRC64NVMEFULL_OBJECT963217d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1170P_Pembrolizumab_Cervical Cancer_Keynote-18_Sukhin.pdf2025-10-30T09:26:13.000Z"58e3ef8de87d2859b3456d474097b83a"CRC64NVMEFULL_OBJECT415959d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD119_Neoadj Chemo+Serplulimab_Rectal Cancer_FIRM_Tingyu Wu.jpg2026-01-21T07:45:05.000Z"d42ee8d99a349f6a729f41ef7a385201"CRC64NVMEFULL_OBJECT2758089d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD11_Atezolizumab+Tiragolumab+CRT_Anal SCC_TIRANUS_Jaume Capdevila.jpg2026-01-21T09:27:55.000Z"6c799701fe5e86cd994bf5d84bee8ebd"CRC64NVMEFULL_OBJECT1790661d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/2025-02-12T13:13:59.000Z"d41d8cd98f00b204e9800998ecf8427e"0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Acute Leukemia French Association.JPG2025-02-12T13:13:59.000Z"89be2dbb49ee5353f1d09f447677d949"60882d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Alissa Pharma.png2026-02-20T10:43:57.000Z"ac2e08ac387b5e0881be91d4c05baf8c"CRC64NVMEFULL_OBJECT5825d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Avacta.png2026-03-19T08:19:26.000Z"fab5d52ba2ebd1e4cd283310a0e4a295"CRC64NVMEFULL_OBJECT6343d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Beijing Biostar Pharmaceuticals.jpg2026-02-08T17:21:12.000Z"bb6011ddb4f530bf11c8c8fa55d402ae"CRC64NVMEFULL_OBJECT12265d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/CSSS.png2026-03-24T14:31:52.000Z"668f190aa5fed6cd5c05a97051f056a7"CRC64NVMEFULL_OBJECT5507d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Cullian.png2026-03-19T09:09:31.000Z"3dfeb510b05aec2de84894d3d5b2cee9"CRC64NVMEFULL_OBJECT4473d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Duke.png2026-03-24T14:28:10.000Z"5733542ebaf48a39998fbbc97eea2787"CRC64NVMEFULL_OBJECT3250d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/ECOG-ACRIN Cancer Research Group.JPG2025-02-12T13:13:59.000Z"fe90b080242073510b35eb79b156d069"47793d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Elevation Oncology.png2026-02-08T17:13:31.000Z"8154eeb637cf3071699d1a6516047d99"CRC64NVMEFULL_OBJECT3674d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias.JPG2025-02-12T13:13:59.000Z"35a983fc26d37ffd7763dcf3538865ca"65440d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Immune Pharmaceuticals.png2026-02-20T11:04:09.000Z"c1867bb3287047a87dc9eef144802ddd"CRC64NVMEFULL_OBJECT2635d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Imperial College Lodon.png2026-03-19T08:01:05.000Z"56212c0ddf0ff39a94ed29d47e94d5ac"CRC64NVMEFULL_OBJECT5840d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Institut du Cancer de Montpellier - Val d'Aurelle.JPG2025-02-12T13:13:59.000Z"7c8ee0f8e51c7acb0f6ee704f00a31f8"38759d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Institute of Hematology & Blood Diseases.png2026-03-24T14:37:08.000Z"bac84878db2759c622d33a31f4206746"CRC64NVMEFULL_OBJECT11827d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Kanisa Pharmaceuticals.JPG2025-02-12T13:13:59.000Z"3d7b184868410b44fed1b6c199bc91fa"36678d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/King Abdullah International Medical Research Center.JPG2025-02-12T13:13:59.000Z"dd3641e52180cc78381aa85c23082b0d"74626d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Loyola University.png2026-03-24T14:25:41.000Z"7737ca767c68891259eefe031268086a"CRC64NVMEFULL_OBJECT10446d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/MabVax Therapeutics.jpg2026-02-20T09:52:39.000Z"ea24416e675ac1b99fa0c2b51e5f4d52"CRC64NVMEFULL_OBJECT6310d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Navrogen.png2026-03-19T07:08:36.000Z"19429afa6e3169183710e90e00e6ae13"CRC64NVMEFULL_OBJECT5019d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Northwestern University.png2026-03-24T14:33:28.000Z"e4e0798ff5ed11fbe0bf88b57f84c96e"CRC64NVMEFULL_OBJECT7988d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Pen.png2026-03-24T11:00:35.000Z"9c9a42bf360a49af39078f47e5da58ff"CRC64NVMEFULL_OBJECT5192d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Pharmatech Oncology.png2026-03-24T12:27:38.000Z"82f49ea931282022bae0f801f62c8bfd"CRC64NVMEFULL_OBJECT7408d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Philochem.png2026-03-19T06:09:26.000Z"c3291b6d0c9378a896a844cc2888d98f"CRC64NVMEFULL_OBJECT4565d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/PreciseMab.png2026-02-20T07:03:39.000Z"b900cce022b1db2a205845e645c3af4b"CRC64NVMEFULL_OBJECT5135d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Scrip Research.png2026-02-20T07:43:04.000Z"a831176b4a3275180859ceb645819671"CRC64NVMEFULL_OBJECT5473d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Southern Hospital of Southern Medical University.JPG2025-02-12T13:14:00.000Z"7598331699d2016705f60c75048d68a4"82444d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/The Cleveland Clinic.JPG2025-02-12T13:14:00.000Z"26c5dac847d89d883157e9dc031a8faa"48325d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/University Hospital, Udine, Italy.JPG2025-02-12T13:14:00.000Z"45603cc14d39760f4ef78a4d3baaa5cd"45428d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Vicero.png2026-02-20T06:25:56.000Z"d33b6bd7c536b2c8efc20e5dc3b1624e"CRC64NVMEFULL_OBJECT12053d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Wshington.png2026-03-24T14:07:50.000Z"1adfb619046f453b76e19b759b5e45cc"CRC64NVMEFULL_OBJECT10563d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/Wyeth.JPG2025-02-12T13:14:00.000Z"1627b06f4f4f89e8b9796cab7d99c788"43829d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-02-2025/beijing_kangmeng_foundation.jpg2026-03-24T07:13:52.000Z"45d201ece7e69b9216bbee106e939fb3"CRC64NVMEFULL_OBJECT59514d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-05-2025/2025-05-12T13:43:10.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-05-2025/Biogenea Pharmaceuticals.png2026-02-16T14:13:17.000Z"13f73a732daeaf3f9900b67cdb4bf4f3"CRC64NVMEFULL_OBJECT5396d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-05-2025/Fukuoka University.JPG2025-05-12T13:43:10.000Z"811748c33275e699ba6ef1b371c025e6"CRC64NVMEFULL_OBJECT49147d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-05-2025/Gynecologic Oncology Group.png2026-03-23T14:28:44.000Z"c57e1eb5cea0c41591643e8f6b90ad0b"CRC64NVMEFULL_OBJECT6191d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-05-2025/Interbalkan Medical Center.png2026-02-16T14:18:59.000Z"df62ffd265ab07a17ba392cc9dac8254"CRC64NVMEFULL_OBJECT4412d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-05-2025/Moderna.png2026-02-16T14:23:26.000Z"16db27cbf435575b5d91ef359768e7d1"CRC64NVMEFULL_OBJECT3716STANDARD12-05-2025/Parexel.png2026-02-16T14:23:19.000Z"f1380033f156409f6465bd09e264f119"CRC64NVMEFULL_OBJECT5014d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-05-2025/PrimeLink BioTherapeutics.JPG2025-05-12T13:43:10.000Z"f8d77cef816b5f9fc5863a1443fcba22"CRC64NVMEFULL_OBJECT52047d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-05-2025/Shanghai Virogin Biotech.jpg2026-02-16T14:19:50.000Z"4373e000ccc477eb0053ad8a3529165b"CRC64NVMEFULL_OBJECT5629d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-05-2025/Sutro Biopharma.png2026-02-16T14:13:27.000Z"c9bafb3be99e7e9ee38465edc558f70e"CRC64NVMEFULL_OBJECT4713d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-05-2025/Suzhou Forlong Biotechnology.png2026-02-16T14:13:45.000Z"21279bfeb25040c7d90e6f4d6f44f718"CRC64NVMEFULL_OBJECT3066d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12-12-2024 Presentation1.jpg2024-12-12T06:03:25.000Z"b78b9e09c4e4aad425197be04d4cade8"52112d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1219TiP_HER2_JSKN003_PROC_Phase 3 study_Wu.pdf2025-10-23T13:23:02.000Z"304b967bed88ffeab74c33a4560a4c40"CRC64NVMEFULL_OBJECT4263746d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1222TiP_Trop2_sac-TMT+Bevacizumab_ psrOvarian Cancer_TroFuse-022 Part 1_Phase 3 Study_Martín.pdf2025-10-23T13:22:08.000Z"16b39897df11c9f3e93efe700a0ee445"CRC64NVMEFULL_OBJECT1242614d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1223TiP_HER2, PD1_Enhertu + Rilvegostomig or pembro_EC_DESTINY-Endometrial01 study_Slomovitz.pdf2025-10-27T06:47:53.000Z"fc7a1b2ad313e5ae157302acac9e0cdb"CRC64NVMEFULL_OBJECT605583d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1224717808 (1).pdf2025-10-24T06:29:18.000Z"b08af18ec094b50cf51cd6e55ab5654f"CRC64NVMEFULL_OBJECT63825d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1225TiP_CLDN-6_TORL-1-23_Ovarian cancer_CATALINA-2ENGOT-ov83_phase 2 study_Winterhoff.jpg2025-10-23T13:55:13.000Z"487b196f7d19c8d6528049ab12391fa0"CRC64NVMEFULL_OBJECT3761818d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1236eTiP_HER2_Disitamab vedotin + Anlotinib_ HER-2_Ovarian cancer_Phase 2 study_Tu.jpg2025-10-23T07:01:05.000Z"2f5a9dad0bd7618c35da3d0c7d6ca623"CRC64NVMEFULL_OBJECT4022343d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD125P_Cemiplimab_NSCLC_EMPOWER-Lung 3_Miranda Gogishvili.pdf2025-12-18T11:30:19.000Z"43d791f422a4f9b1809783395561e5a1"CRC64NVMEFULL_OBJECT329154d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD128P_Camrelizumab_Thalidomide for preventing reactive cutaneous capillary endothelial proliferation_NCT06231680_XiaoFu.pdf2025-12-18T11:54:01.000Z"ff8abcfef3a6beb2337bd586052ae42a"CRC64NVMEFULL_OBJECT221561d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12982-Article Text-89109-1-10-20251106 (3).pdf2025-12-01T12:23:50.000Z"d631604c924f8acdf6238d7660823b47"CRC64NVMEFULL_OBJECT4536748d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD12982-Article Text-89109-1-10-20251106.pdf2025-11-10T09:08:48.000Z"d631604c924f8acdf6238d7660823b47"CRC64NVMEFULL_OBJECT4536748d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD129_Precemtabart tocentecan (Precem TcT, M9140) in patients with mCRC_Kopetz.jpg2026-01-12T09:47:14.000Z"f8c84b2899cd546ead0b5b8ed93c886d"CRC64NVMEFULL_OBJECT2145542d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1316eTiP_ROR1_CS5001_aSolid tumours and Lymphomas_Phase 1b trial_Song.jpg2025-10-23T14:35:08.000Z"947c1c4ed1e2e164dece2e7c27a6aa8f"CRC64NVMEFULL_OBJECT5172792d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1328MO_Pembrolizumab_HNSCC_Philipp Schubert.pdf2025-11-05T10:31:50.000Z"fbecdec302f9ee4a49fb27c855534d2e"CRC64NVMEFULL_OBJECT814979d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1329MO_Nectin 4_Enfortumab vedotin + Pembro_rm HNSCC_EV-202 trial result_Swiecicki.pdf2025-10-24T11:00:10.000Z"20389e1a7af493098aa4100c11b0e238"CRC64NVMEFULL_OBJECT2167823d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD132_Exposure-response analyses from a randomized dose optimization study of telisotuzumab adizutecan_Alshaer.jpg2026-01-12T10:36:12.000Z"16db780c3228b611e9a5a758c31e6a57"CRC64NVMEFULL_OBJECT1879960d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1338P_Dostarlimab_HNSCC_Luigi Lorini.pdf2025-10-30T09:56:50.000Z"c2627d52548da81fdb5beb51f5b4dfe4"CRC64NVMEFULL_OBJECT506225d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1348MO_Atezolizumab_HNSCC_Psyrri.pdf2025-10-30T10:22:27.000Z"f00a8ced44cbc8b8cebd6ae84ac33928"CRC64NVMEFULL_OBJECT592762d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD135P_Tislelizumab_GC_Xiangdong Cheng.pdf2025-10-30T06:33:44.000Z"48317b28473d46b1a07cb0dbbb30545a"CRC64NVMEFULL_OBJECT282124d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1378P_Envafolimab_LANPC_EASY001_Wang.pdf2025-10-30T10:41:33.000Z"7aaf712349ab1c379fe2c855d8f29f5c"CRC64NVMEFULL_OBJECT1610083d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD137_Pembro_CRC_Andre.jpg2026-01-21T08:37:04.000Z"1615e8aac99898ea45671ba5d7816a9a"CRC64NVMEFULL_OBJECT1433142d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD139P_TMB_Solid_Andrea Botticelli.pdf2025-11-05T11:45:05.000Z"367b954effb791b8f0ecdcd26468f9ce"CRC64NVMEFULL_OBJECT795499d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD14 1.jpeg2025-05-14T12:26:46.000Z"4297d38d986b70e03fff95e1608a206d"CRC64NVMEFULL_OBJECT2765775d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD143_IMpower010_Genomic Profiling and Clinical Outcomes With Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer_Wakelee.jpeg2025-06-04T15:01:31.000Z"5756fc0c1b9e9063652cd74d71bebe07"CRC64NVMEFULL_OBJECT3317246d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1485P_Atezolizumab_HCC_Alexander B. Philipp.pdf2025-10-30T11:41:45.000Z"88f70703f55fcba337448fac58bc92fc"CRC64NVMEFULL_OBJECT904374d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD15-05-2025/2025-05-15T13:19:54.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD15-05-2025/Abotte.png2026-02-24T07:37:35.000Z"9d97064c16bf9de6cdf659f3d6797fcc"CRC64NVMEFULL_OBJECT3116d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD15-05-2025/Anaveon.png2026-03-25T11:07:27.000Z"9b6667a3abb0ec79cf09f29c3045f9fe"CRC64NVMEFULL_OBJECT5289d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD15-05-2025/Annexin.png2026-02-24T06:47:52.000Z"4768784a01693065c18b7c741ce65b87"CRC64NVMEFULL_OBJECT5827d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD15-05-2025/CatenaBio.JPG2025-05-15T13:19:54.000Z"6bf976cda67291a6016cc5f346dd8a5d"CRC64NVMEFULL_OBJECT34415d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD15-05-2025/Celgen.png2026-03-25T13:37:27.000Z"cdffdac7ff319496a3786a2123034825"CRC64NVMEFULL_OBJECT6985d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD15-05-2025/NeoRx Corporation.jpg2026-03-05T11:02:36.000Z"1b6609613bea2fa7379a43361d2c7725"CRC64NVMEFULL_OBJECT6337d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD15-05-2025/Philogen.jpg2026-03-25T11:33:52.000Z"99a0e9ce49c707d45c4d448c63d2842d"CRC64NVMEFULL_OBJECT8011d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD15-05-2025/Shanghai ChemPartner.JPG2025-05-15T13:19:54.000Z"af7fa81786614c08e2eb549a712fea7f"CRC64NVMEFULL_OBJECT48593d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD15-05-2025/Stem.png2026-03-25T12:03:26.000Z"2598cedc02c55ea78a3f2692ec4c843b"CRC64NVMEFULL_OBJECT2819d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD15-05-2025/TAE Life Sciences.png2026-02-24T07:58:28.000Z"3acf9970f7c68eff02629379df091e80"CRC64NVMEFULL_OBJECT6237d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1505P_Atezolizumab_HCC_Cheng Ean Chee.pdf2025-10-30T12:26:20.000Z"abf84906110d6e1c174afb6217f62ef0"CRC64NVMEFULL_OBJECT2409074d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1519_Next-generation tumor-specific anti-CD30 ADC as a new therapy in hemato-oncology_Marines.png2026-01-04T13:43:24.000Z"559d6437c950f5beaa92f99ff875cdd4"CRC64NVMEFULL_OBJECT1873281d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1520MO_Atezolizumab_Solid_Silva.pdf2025-11-05T05:51:21.000Z"88859061baa49f5c3c6b04f6b4339445"CRC64NVMEFULL_OBJECT1249027d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1522MO_INCA33890_Solid_Garralda.pdf2025-11-06T11:41:09.000Z"1ea4638289a953dbccae114ef22e91c7"CRC64NVMEFULL_OBJECT891184d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1527_A combination strategy of inotuzumab ozogamicin (InO) and BCL-2 family inhibitors_Akaogi.png2026-01-04T13:05:08.000Z"7365b535717bbd3e7962760a64bd8289"CRC64NVMEFULL_OBJECT1747722d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD152_Final analysis of the Phase III GHSG HD21 trial_Ferdinandus.pdf2025-12-18T14:02:46.000Z"78da4587c9b21a3dd174b523457a2be7"CRC64NVMEFULL_OBJECT2370354d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD153_Interim PET-adapted de-escalation chemotherapy regimen for advanced stage classical Hodgkin lymphoma using brentuximab vedotin_Lee.pdf2025-12-19T07:21:41.000Z"d5d23f99e9be780380e41809632ec2b4"CRC64NVMEFULL_OBJECT2478087d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1556.png2025-06-18T13:57:32.000Z"6ce93b5caffbb72747ee820ee8630dce"CRC64NVMEFULL_OBJECT3622988d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1559.jpeg2025-05-16T07:47:37.000Z"df356e88fb85a965c09375ae5f69fc41"CRC64NVMEFULL_OBJECT2838515d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD155_First-in-human, open-label, Phase 1 study of a novel CD30-directed with a topoisomerase 1 inhibitor payload, PF-08046044 (35C)_Thiruvengadam.pdf2025-12-19T13:03:46.000Z"5ed4fa70320e90b74259570c6f532f5f"CRC64NVMEFULL_OBJECT1657981d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1560.jpeg2025-05-16T13:30:26.000Z"7670c0a92a6fc26384f9ff31a79ef84e"CRC64NVMEFULL_OBJECT2154125d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1563.jpeg2025-05-16T08:29:19.000Z"e3dd8def41912ad72816565321fa38bb"CRC64NVMEFULL_OBJECT2915376d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1565.jpeg2025-05-14T08:52:31.000Z"de0dda4147c948a28f4619fc033cf190"CRC64NVMEFULL_OBJECT2909584d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1567_GLR1059, next-generation nectin-4-targeted ADC with a novel mechanism-of-action payload, demonstrated significantly potent anti-tumor efficacy and reduced toxicity in preclinical evaluation_Jiao.jpeg2025-05-15T05:40:13.000Z"22642b49591eb68a064e55a4078559f2"CRC64NVMEFULL_OBJECT2430138d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1567_The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential_Goulart.png2025-12-22T04:39:52.000Z"d403cdf2155b9d58bc3fc353208f33ca"CRC64NVMEFULL_OBJECT1159692d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1569.jpeg2025-05-08T08:17:40.000Z"a5b4ef62c991d67607f60c5c7376c2bc"CRC64NVMEFULL_OBJECT2710659d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1570.jpeg2025-05-15T13:14:24.000Z"034cadfe40f878fc5ce07b4e8f983360"CRC64NVMEFULL_OBJECT2719967d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1573.jpeg2025-05-16T13:36:51.000Z"f3bc8fce5db8f70be45c18d5b52675f8"CRC64NVMEFULL_OBJECT2275932d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1578.jpeg2025-05-19T17:47:06.000Z"e446579cdf9cd2cf96cdf2060f5a94b7"CRC64NVMEFULL_OBJECT2455497d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1579.jpeg2025-05-15T13:19:39.000Z"f23bcdf74eea059f8f328b850ba3b1c0"CRC64NVMEFULL_OBJECT2656017d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1580_HuB14-VA-PL2202.jpeg2025-05-14T11:17:12.000Z"d19985df2252081fcea74bf53d06935e"CRC64NVMEFULL_OBJECT3185882d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1581.jpeg2025-05-16T12:33:00.000Z"77c3c7753b74a5b0771f09dadfecd488"CRC64NVMEFULL_OBJECT2570489d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1586.jpeg2025-05-27T07:13:46.000Z"8912e21a6165d7212ca332fbf31c4a10"CRC64NVMEFULL_OBJECT2606787d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1596eTiP.jpg2025-10-21T12:43:31.000Z"f5079d47c273d38ef104430d0cd69620"CRC64NVMEFULL_OBJECT732890d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD159_Activity of DEM301, a novel anti TXX antibody-drug conjugate for the treatment of gastrointestinal tumors_Carden.jpg2026-01-12T11:01:20.000Z"26562c44ceed0e3cfbd6dbfd3c2a3265"CRC64NVMEFULL_OBJECT1832658d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/2025-04-16T10:43:48.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Actuate Therapeuticsyte Corporation.png2025-04-16T13:46:20.000Z"a7085f4e400205815e8b329e722c8eda"CRC64NVMEFULL_OBJECT6190d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Alberta Cancer Foundation.png2025-04-16T12:19:11.000Z"32bf9bc8f1fda74cab8666234cba5356"CRC64NVMEFULL_OBJECT13405d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/American Cancer Society.jpg2025-04-16T11:13:47.000Z"12c4be0655408207730541819c45133b"CRC64NVMEFULL_OBJECT70005d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Baili-Bio (Chengdu) Pharmaceutical.png2025-04-16T12:23:34.000Z"4a9e13dea46a83fbfb0f26c25e501bd9"CRC64NVMEFULL_OBJECT3277d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Biohaven Therapeutics.png2025-04-16T12:27:51.000Z"2547c0407f0fc0f0860778ebe59baf31"CRC64NVMEFULL_OBJECT4115d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Checkmate Pharmaceuticals.jpg2025-04-16T11:15:21.000Z"325a5fc9f8ee341b5dda97d870db84db"CRC64NVMEFULL_OBJECT56326d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Clinigen.jpg2025-04-16T12:32:02.000Z"425936461bbe4734626c237d8914d274"CRC64NVMEFULL_OBJECT5759d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Cooperative Trials Group for Neuro-Oncology.jpg2025-04-16T11:30:23.000Z"436eefe50339b1a0e130c56e02de582a"CRC64NVMEFULL_OBJECT58634d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Eurofins.png2025-04-17T06:12:59.000Z"eb0c9835ea0da365c2e6a02305428ad4"CRC64NVMEFULL_OBJECT3332d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/First Affiliated Hospital, Sun Yat-Sen University.png2025-04-16T13:38:43.000Z"23c3844c91b54f40c9313a89fc041401"CRC64NVMEFULL_OBJECT2945059d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/French Lung Cancer Group.jpg2025-04-16T11:38:34.000Z"b0e845256ecdcbbab2e269971a86d8b3"CRC64NVMEFULL_OBJECT61261d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/GWT-TUD GmbH.png2025-04-16T12:41:42.000Z"5aee848e115593e29074196635796a03"CRC64NVMEFULL_OBJECT2990d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/GeneQuantum Healthcare.jpg2025-04-16T12:36:54.000Z"16725c494bf254710cea78931b31644f"CRC64NVMEFULL_OBJECT7598d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Gyeongsang National University Hospital.jpg2025-04-16T13:26:44.000Z"c988ab2b7d7f6c8a59af05f5edc3846c"CRC64NVMEFULL_OBJECT68188d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Handok.jpg2025-04-16T11:47:11.000Z"e6a3bc5e70300a4ca8046b44d4047efd"CRC64NVMEFULL_OBJECT57392d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/ICON.jpg2025-04-16T12:48:58.000Z"f61a2eae9f56bd00a4b1651597e7d121"CRC64NVMEFULL_OBJECT23073d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/IQVIA.jpg2025-04-16T12:21:04.000Z"bce459e5bddc3091af1e84603f989ca3"CRC64NVMEFULL_OBJECT43591d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/ImaginAb.jpg2025-04-16T11:49:53.000Z"1a120630953f8d6770b9bc18daccb05b"CRC64NVMEFULL_OBJECT55136d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Inovio Pharmaceuticals.png2025-04-16T12:52:00.000Z"bbfa753f2ba72c15bb8a7ee08f993012"CRC64NVMEFULL_OBJECT91851d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Institut de Recherches Internationales Servier.jpg2025-04-16T11:52:52.000Z"99d0030f619afcdd25f641d2ac34eaca"CRC64NVMEFULL_OBJECT55411d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Jiangsu Aosaikang Pharmaceutical.jpg2025-04-16T13:51:10.000Z"f68910db27389f6425e092d3bf9e6f21"CRC64NVMEFULL_OBJECT7588d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Jubilant Biosys.jpg2025-04-16T13:30:27.000Z"87e1a85c6a8ea05891e17dff8aba2aa2"CRC64NVMEFULL_OBJECT64026d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/2025-04-16T14:36:48.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/Institut Bergonié.jpg2025-04-16T14:38:22.000Z"3350847faa0921bc9bc683960f0c1a9b"CRC64NVMEFULL_OBJECT76108d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/Jiangsu Provincial People's Hospital.jpg2025-04-16T14:38:22.000Z"1d23184d823db18f3fcaf578711ca81c"CRC64NVMEFULL_OBJECT55823d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/KisoJi Biotechnology.jpg2025-04-16T14:38:22.000Z"272a3509f45360456aec36468147941f"CRC64NVMEFULL_OBJECT66167d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/Liaoning Cancer Hospital and Institute.jpg2025-04-16T14:38:22.000Z"7ad18a182bc7557c611a8ef2c8d441e1"CRC64NVMEFULL_OBJECT80399d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/Nanjing Medical University.jpg2025-04-16T14:38:22.000Z"43c5e4613c6398c303551bbd741eb5c6"CRC64NVMEFULL_OBJECT75144d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/Novatek Pharmaceuticals.jpg2025-04-16T14:38:23.000Z"610318306fbcf29ed6ed3afc0ba2a1fa"CRC64NVMEFULL_OBJECT71066d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/Pacific Pediatric Neuro-Oncology Consortium.png2025-04-16T14:38:23.000Z"907aa63db1338292e095352ef8dc1656"CRC64NVMEFULL_OBJECT5668d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/Shandong New Age Pharmaceutical.jpg2025-04-16T14:38:23.000Z"918f02effa02669a60ee91b1a99c86c9"CRC64NVMEFULL_OBJECT61251d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/Shengjing Hospital.jpg2025-04-16T14:38:23.000Z"350ec2ddb691de6f0730e164fb4a7f31"CRC64NVMEFULL_OBJECT69899d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/Sun Yat-sen University.jpg2025-04-16T14:38:23.000Z"bfdf791c5a0c0faccb6ac64872b66a15"CRC64NVMEFULL_OBJECT93529d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/TaiRx.jpg2025-04-16T14:38:23.000Z"d8106ecfb7f7812461e16c3773a15092"CRC64NVMEFULL_OBJECT42383d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/The First Affiliated Hospital of University of South China.jpg2025-04-16T14:38:23.000Z"b236664176cb72d87a070b3f9156dfdb"CRC64NVMEFULL_OBJECT98547d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/Thermo Fisher Scientific.jpg2025-04-16T14:38:23.000Z"38981708f468fd131af072506a30361a"CRC64NVMEFULL_OBJECT55576d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/Universität des Saarlandes.jpg2025-04-16T14:38:23.000Z"7c38112221532fece1b4233f5186ba26"CRC64NVMEFULL_OBJECT94246d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Logos 15-30/Xcovery Holdings.png2025-04-16T14:38:23.000Z"82ab4b25e96cce80bc2e5ad342a61de2"CRC64NVMEFULL_OBJECT7869d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/LumaBridge.jpg2025-04-16T11:56:19.000Z"90dcab9d4076533debbbb99475864cf0"CRC64NVMEFULL_OBJECT55635d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Merck.jpg2025-04-16T11:59:51.000Z"5597452b7d6850af1ee605ef3374eee6"CRC64NVMEFULL_OBJECT41900d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Myriad Genetic Laboratories.png2025-04-16T13:08:35.000Z"e340dfa64c1901359d367228d6d84491"CRC64NVMEFULL_OBJECT6501d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/NanoPass Technologies.jpg2025-04-16T10:43:58.000Z"761d014e21df69d564d6378a1cccc243"CRC64NVMEFULL_OBJECT45096d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Nanocarry Therapeutics.jpg2025-04-16T12:15:09.000Z"4ad079aaa480b2e0844e922d674d5bb7"CRC64NVMEFULL_OBJECT47713d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/NeoTX Therapeutics.jpg2025-04-16T13:14:23.000Z"4b0769dee1fc56a074a4e37e554b6123"CRC64NVMEFULL_OBJECT33396d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Ontario Institute for Cancer Research.png2025-04-16T13:17:45.000Z"183d9a9554a254eaf116460b807e172b"CRC64NVMEFULL_OBJECT7786d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Parexel.jpg2025-04-16T12:23:17.000Z"edeec55f2d2d77a66eff0386c65a0903"CRC64NVMEFULL_OBJECT41112d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Pivotal S.L..png2025-04-16T13:21:10.000Z"6f5debe2fd2f6e2830164368fb0e2621"CRC64NVMEFULL_OBJECT8372d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Precision Oncology.jpg2025-04-16T12:29:00.000Z"38ce3bd790fbfc4892a0033c913ea963"CRC64NVMEFULL_OBJECT47784d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/SCRI Development Innovations, LLC.png2025-04-16T14:00:02.000Z"1fdb5e43be53922ba7a4c40c13893ecb"CRC64NVMEFULL_OBJECT6286d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Servier.png2025-04-16T13:24:50.000Z"b450895a48408da465041d85e91a4f25"CRC64NVMEFULL_OBJECT5003d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Shandong New Time Pharmaceutical.jpg2025-04-16T12:37:30.000Z"c942a3262c2f747a7e3d92279c0a0469"CRC64NVMEFULL_OBJECT85015d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Shenzhen Hank Bioengineering Institute.jpg2025-04-16T13:29:30.000Z"18538b18cacbc2a6e0ece838617f5e44"CRC64NVMEFULL_OBJECT54306d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Slagelse Hospital.jpg2025-04-16T12:43:10.000Z"5e051f1bf83e476a143c9b0ca978634d"CRC64NVMEFULL_OBJECT45185d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Symphogen AS.png2025-04-16T13:35:18.000Z"1a5372cf21ffbe2af15a4a11af49cc59"CRC64NVMEFULL_OBJECT6972d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/The Lymphoma Academic Research Organisation.jpg2025-04-16T14:26:31.000Z"9b634044e06cfdb9c91a7259c0ac595d"CRC64NVMEFULL_OBJECT71723d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/The Pregene (ShenZhen) Biotechnology Company.jpg2025-04-16T12:48:09.000Z"d759f9482c44b845f23c5d89aa788130"CRC64NVMEFULL_OBJECT36413d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/United States Department of Defense.jpg2025-04-16T13:41:39.000Z"217438a598af36f526e434491bf10986"CRC64NVMEFULL_OBJECT22631d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/University of California, San Francisco.png2025-04-17T06:21:49.000Z"86cd93f7a38e566555f2bca571b1a1d1"CRC64NVMEFULL_OBJECT5695d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Universitätsklinikum Hamburg-Eppendorf.jpg2025-04-16T12:50:21.000Z"80b1ad1334b9623a0fda7bf5c4ede047"CRC64NVMEFULL_OBJECT59913d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Wu Jieping Medical Foundation.png2025-04-16T13:44:00.000Z"36c62518683489aa59b4532f1fc1b3ee"CRC64NVMEFULL_OBJECT7126d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/Xynomic Pharmaceuticals.jpg2025-04-16T13:53:09.000Z"08723223a5b3829919dbab29e53ed9bf"CRC64NVMEFULL_OBJECT4475d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD16 april logo/pp.jpg2025-04-16T11:25:16.000Z"42055bec022714760c4fd31193dc2c04"CRC64NVMEFULL_OBJECT75351d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1605MO_Cemiplimab_Melanoma_Ascierto.pdf2025-11-05T09:35:24.000Z"7f51c34288c611e98197829f8fe7804f"CRC64NVMEFULL_OBJECT723520d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD160MO.pdf2026-01-18T16:05:23.000Z"3d1713e1f6db2eddb75987c5c274c866"CRC64NVMEFULL_OBJECT585317d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1611_Pembrolizumab_Melanoma_Alexander M.M. Eggermont.pdf2025-10-31T06:17:34.000Z"c9f454694135987410049e6ad2035f57"CRC64NVMEFULL_OBJECT363120d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1627P_Toripalimab_Melanoma_Zou.pdf2025-10-30T14:11:25.000Z"93ba5442a7bac9cb11848046f048bb5e"CRC64NVMEFULL_OBJECT316825d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD163MO_anti-TIGIT, PVRIG, sintilimab_solid tumors_J. Xue.pdf2026-03-19T07:20:44.000Z"b7d9c420f64f72b18bf6fa8ce0cb9fc3"CRC64NVMEFULL_OBJECT786597d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD164.jpg2026-03-02T13:08:01.000Z"e556bc8a03f2b82ffbdc893584674eee"CRC64NVMEFULL_OBJECT312439d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1656_ITCC-101 APAL2020D- A randomized Phase 3 trial of fludarabine,cytarabine,gemtuzumab ozogamycin_Ishimaru.png2025-12-22T05:08:54.000Z"3fd43deeb9d8cd3382722976539ab718"CRC64NVMEFULL_OBJECT1302480d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1660P_Cemiplimab_SCC_Danny Rischin.pdf2025-10-31T06:39:31.000Z"dadd5cb762adeab7528b40cd66ce1980"CRC64NVMEFULL_OBJECT354322d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD170.jpg2026-03-06T07:51:39.000Z"f9fc9c5d60b49074f2204f458400e40d"CRC64NVMEFULL_OBJECT1837855STANDARD1705.jpeg2025-05-08T11:26:10.000Z"4edec52a81a2a02a0f519ab688c9f559"CRC64NVMEFULL_OBJECT2757588d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD177Lu-P17-087.jpg2025-11-18T14:33:53.000Z"9dadb55bdd784e2465a8ee8b4149203f"CRC64NVMEFULL_OBJECT43463d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD177Lu-P17-088.jpg2025-11-18T14:31:41.000Z"d1d71763961e23026bc2781e2e4e928b"CRC64NVMEFULL_OBJECT48975d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD177Lu-PNT6555 Stucture.jpg2025-12-08T05:41:09.000Z"bc42c8aa04612f58f8fcf8fe3e77e884"CRC64NVMEFULL_OBJECT30531d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD177lu NM.jpg2025-12-03T03:45:13.000Z"f5433b40bccc1115ca295ea87668b999"CRC64NVMEFULL_OBJECT36429d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD177lu1009.jpg2025-12-08T11:36:12.000Z"befb3da7e3871d2f582783666bb2174e"CRC64NVMEFULL_OBJECT49531d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1785.jpeg2025-05-08T10:28:24.000Z"b5692035b0683b79dc33a28eaf83dd03"CRC64NVMEFULL_OBJECT2616857d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1790.jpeg2025-05-16T07:28:56.000Z"97780fa49898c861e49b1b893c98b1fc"CRC64NVMEFULL_OBJECT2654667d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1793.jpeg2025-05-16T08:32:48.000Z"abb817978e44672aa93e7e626b545e45"CRC64NVMEFULL_OBJECT3002102d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1798.jpeg2025-05-16T12:36:10.000Z"164ed06702ebdfad57e8229436649538"CRC64NVMEFULL_OBJECT3216632d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1799.jpeg2025-05-08T07:20:32.000Z"02f478c786987046bc73985c3e7cfa9c"CRC64NVMEFULL_OBJECT2946835d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/2024-11-18T11:33:07.000Z"d41d8cd98f00b204e9800998ecf8427e"0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/Gentech.png2025-03-25T11:09:06.000Z"8d990f16a104e40f50f3e94c1be3df7b"CRC64NVMEFULL_OBJECT9755d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/Miami Cancer Institute.jpg2024-11-25T07:40:05.000Z"0ce772627695ecbc70ba9ed932f64d46"59174d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/2024-11-18T11:33:31.000Z"d41d8cd98f00b204e9800998ecf8427e"0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/ENGOT.jpg2024-11-18T11:33:31.000Z"47b94132fff24e741b02a8bdf2f438c2"24233d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/Epimab.jpg2024-11-18T11:33:31.000Z"95ac6ff1c8831c9d50d3a7cc17d4c46d"8189d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/GenSci.jpg2024-11-18T11:33:32.000Z"7aa6e7aa308066d47a7eb43ebc0f717a"13566d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/GeneQuatum Healthcare.jpg2024-11-18T11:33:32.000Z"3865eaba0b68cacbb5963d421e0ca832"58819d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/GlycoNex.jpg2024-11-18T11:33:32.000Z"20ac7a6ed8a9f9ab77a2a7820809ad98"25152d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/HangzhDAC biotech.jpg2024-11-18T11:33:33.000Z"7d876749523e8cce57f8d61078aa9569"67104d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/KCR.jpg2024-11-18T11:33:33.000Z"dc2a24fe7cb03625a053e03152cfca1c"50340d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/Moderna TX.jpg2024-11-18T11:33:33.000Z"9812f3b8ae40b940f17654858eae0471"55438d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/Navy general hospital.jpg2024-11-18T11:33:34.000Z"b38b13e5ee10fa586ad43211836969ae"44574d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/Pharm-Olam International.jpg2024-11-18T11:33:34.000Z"ee16249adbdde96af1422ded2c56cd04"84988d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/Stichting European Myeloma Network.jpg2024-11-18T11:33:35.000Z"6c7c82feef70e0f4ea7d0419660a9b36"61842d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/Theradex.jpg2024-11-18T11:33:35.000Z"c6a28d658091dfbc15d4ca910cbbd1af"63458d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/genmab.jpg2024-11-18T11:33:32.000Z"774b25cab642e555d8e273026361c35d"35008d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/New logo 18 nov/moderna.jpg2024-11-18T11:33:34.000Z"9812f3b8ae40b940f17654858eae0471"55438d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/bright biologics.jpg2024-11-21T13:31:38.000Z"673499fde26d39cb3856d7a90fa7c471"66970d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/dac.jpg2024-11-20T09:33:08.000Z"56f26b9e9f6cce3bab87f7cf1def75f3"73414d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/rework logo/2024-11-18T12:17:22.000Z"d41d8cd98f00b204e9800998ecf8427e"0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/rework logo/KCR.jpg2024-11-18T12:17:23.000Z"cd9fc969782bd8a30d81f383db6185ee"71682d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/rework logo/Navy general hospital.jpg2024-11-18T12:17:23.000Z"f24f2c5689fc004f5cd4e5ffc04b5565"60191d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/rework logo/Stichting European Myeloma Network.jpg2024-11-18T12:17:23.000Z"57eb2c32368bb7cfed17aa3ffd6fff95"77653d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/rework logo/genequantum.jpg2024-11-18T12:17:22.000Z"1828020f576f7ee124c57b20623259e1"79627d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD18 th nov new logo/starpharma.jpg2024-11-19T14:20:22.000Z"34727f9b2c99b16a4666fbca81f2a2b7"54686d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1804.jpeg2025-05-08T10:30:48.000Z"c4312599bb1fbd74ad7cff92d0d0e348"CRC64NVMEFULL_OBJECT2373807d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1805.jpeg2025-05-08T09:44:23.000Z"4635c172a8be02978bf917b86b97c913"CRC64NVMEFULL_OBJECT3049903d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1808_A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC)_Yi.png2025-12-19T14:31:31.000Z"1cb51e0b89ddcdab5d6f81596fbc9b8e"CRC64NVMEFULL_OBJECT1398618d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD181P_durvalumab_SCC_Phase II trial of first-line durvalumab and chemotherapy_Sei Kok.pdf2025-12-17T11:59:41.000Z"010cd38985b45097ab1a98b8105d3527"CRC64NVMEFULL_OBJECT508058d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD183.jpg2026-03-10T13:40:47.000Z"bd6bd94cedd6a063edac5fc09b3bfd8f"CRC64NVMEFULL_OBJECT2067969d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1851MO_Pembrolizumab_NSCLC_Ilias Houda.pdf2025-11-05T11:24:16.000Z"c3e5e77b90b6a9e3dbaf57721674153e"CRC64NVMEFULL_OBJECT1082085d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1858P_Tislelizumab_NSCLC_William William.pdf2025-10-31T09:27:48.000Z"db29be72a3b31b8a368af1f1b59df4f3"CRC64NVMEFULL_OBJECT1001912d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1870P_Nivolumab_NSCLC_Tomonori Makiguchi.pdf2025-10-31T10:11:19.000Z"01af270581f2d4392cc2f436a5361c42"CRC64NVMEFULL_OBJECT276568d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD187_Cabozantinib_ Nivo_Prostate Cancer_ph2 study of cabozantinib and nivolumab in prostate cancer_Panian.jpg2026-03-05T17:38:54.000Z"389d8b1b8b3bd6d5a690ad7229223fb0"CRC64NVMEFULL_OBJECT2194693d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1893P_pembrolizumab_NSCLC_Edurne Arriola Aperribay.pdf2025-11-04T05:53:45.000Z"155c5761154fb21b6557f1af1f70e012"CRC64NVMEFULL_OBJECT334223STANDARD19 march 2025/2025-03-19T06:45:58.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/Aichi Cancer Center.jpg2025-03-20T05:00:17.000Z"a8633568dd66814c030e87c80ff8e7a4"CRC64NVMEFULL_OBJECT40591d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/Australasian Myeloma Research Consortium.jpg2025-03-20T04:56:31.000Z"2a176bc3139382ca9b39d6d652c0c531"CRC64NVMEFULL_OBJECT61969d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/Beijing hospital.jpg2025-03-19T07:51:05.000Z"7769944949157ebb417540eb5be8644b"CRC64NVMEFULL_OBJECT49336d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/DIPARTIMENTO DI MEDICINA.jpg2025-03-19T17:39:54.000Z"7db1a213309347bba7f9b7adba7061c4"CRC64NVMEFULL_OBJECT104557d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/Dokkyo medical university.jpg2025-03-19T07:51:05.000Z"d93c2f9f43fac3ccba01c1f4fd9192ca"CRC64NVMEFULL_OBJECT42329d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/Fondazione Policlinico Universitario Agostino Gemelli IRCCS.jpg2025-03-19T17:33:34.000Z"758ecc03da0d549b1555844d11e569fc"CRC64NVMEFULL_OBJECT112227d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/GPOH gGmbH.jpg2025-03-19T17:43:25.000Z"2ffc495b7009e4ef937bdac0d6c788fa"CRC64NVMEFULL_OBJECT41112d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/ISTITUTO EUROPEO DI ONCOLOGIA.jpg2025-03-19T07:51:05.000Z"c316430944d6729cbdac802941ed4243"CRC64NVMEFULL_OBJECT55246d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/National cancer center japan.jpg2025-03-19T07:51:06.000Z"a068718d20004cae3a36bbc34504f3f5"CRC64NVMEFULL_OBJECT39975d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/National cancer center.jpg2025-03-19T07:51:06.000Z"1e53dede3690327c790e244807261896"CRC64NVMEFULL_OBJECT67931d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/National hospital cancer.jpg2025-03-19T07:51:06.000Z"6bfb508ff036cff6fda0927f572a2032"CRC64NVMEFULL_OBJECT63814d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/SHANGHAI.jpg2025-03-19T15:17:04.000Z"49a9c4deb7d0825d341c97435d13e021"CRC64NVMEFULL_OBJECT54504d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/The First Affiliated Hospital of Wenzhou Medical University.jpg2025-03-19T17:48:28.000Z"dbad381f6cb716e6bc4e2333877d92a1"CRC64NVMEFULL_OBJECT83825d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/UM.jpg2025-03-19T15:07:59.000Z"257a8fec5bfa9b2be260e91498cf7a83"CRC64NVMEFULL_OBJECT42363d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/Universita' Degli Studi Di Perugia.jpg2025-03-20T04:58:50.000Z"bcd92b81fed5d804705aeb5a8b028e82"CRC64NVMEFULL_OBJECT61788d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/asian medical center.jpg2025-03-19T07:51:05.000Z"c721d85c17a7ea737e4899fb2b743da1"CRC64NVMEFULL_OBJECT67952d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/herlev hospital.jpg2025-03-19T07:51:05.000Z"3b0ec1b2dda9d6883bcf99216eeb1ad1"CRC64NVMEFULL_OBJECT45010d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/johns sidney.jpg2025-03-19T17:36:57.000Z"87c04872a428a453757e3566739882d3"CRC64NVMEFULL_OBJECT56615d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/kooperativni.jpg2025-03-19T07:51:05.000Z"e9d3ec10bac8b1cba05edf36d764f22a"CRC64NVMEFULL_OBJECT45863d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/kyoto univeristy.jpg2025-03-19T07:51:05.000Z"8cf47d7a9f898ddd59d8bace221f00f8"CRC64NVMEFULL_OBJECT40181d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/samsung medical centre.jpg2025-03-19T17:35:31.000Z"7a75299bed3ef0f7d8756e29b89410bd"CRC64NVMEFULL_OBJECT61646d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/the clatterbridge cancer center.jpg2025-03-19T07:51:06.000Z"7a847ad3908b3dcd885787c8146fd281"CRC64NVMEFULL_OBJECT48642d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19 march 2025/yonsei university.jpg2025-03-19T07:51:06.000Z"159cb71393f12ff60301b2994e3902c0"CRC64NVMEFULL_OBJECT57946d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/2025-03-19T07:02:21.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/20-03-2025/2025-03-20T04:59:12.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/20-03-2025/Associacio Per A La Recerca Oncologica.JPG2025-03-20T04:59:12.000Z"a13df73a386e0ef5a526cfe03304eae9"CRC64NVMEFULL_OBJECT47218d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/20-03-2025/Ceska Myelomova Skupina z.s..JPG2025-03-20T04:59:12.000Z"90ec5f41238197399d51b7e53d6d5d82"CRC64NVMEFULL_OBJECT65370d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/20-03-2025/Erasmus Universitair Medisch Centrum Rotterdam.JPG2025-03-20T04:59:12.000Z"f8fac2cab67b2553d2f1159cb9ed8165"CRC64NVMEFULL_OBJECT68682d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/20-03-2025/Med. Univ. Wien, Klinik f. Innere Medizin I, Onkologie.JPG2025-03-20T04:59:12.000Z"2dd4e670d0016c2647e09d263a51eed4"CRC64NVMEFULL_OBJECT76692d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/20-03-2025/Mie University Hospital.JPG2025-03-20T04:59:13.000Z"368bda4fbb1bdc09f76599bfc9512a4c"CRC64NVMEFULL_OBJECT48479d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/20-03-2025/The First Affiliated Hospital of Henan University of Science and Techno.JPG2025-03-20T04:59:13.000Z"feed4af28b527cb91c61e0445b7b56d7"CRC64NVMEFULL_OBJECT44072d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/Hamamatsu University School of Medicine.JPG2025-03-19T07:02:22.000Z"3b0f8da5b27787a18dc99da7d18551a7"CRC64NVMEFULL_OBJECT53324d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/Kagoshima University Hospital.JPG2025-03-19T07:02:22.000Z"73a47f22e36fc3fb191157f24cd0c145"CRC64NVMEFULL_OBJECT56462d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/National Center for Child Health and Development.JPG2025-03-19T07:02:22.000Z"270fde99867ddc4eadbb4816d62293ab"CRC64NVMEFULL_OBJECT59666d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/Okayama University.JPG2025-03-19T07:02:22.000Z"16bf77134bb6c24dbf2485f373d994d1"CRC64NVMEFULL_OBJECT46793d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/Princess Máxima Center for Pediatric Oncology.JPG2025-03-19T07:02:22.000Z"7f9b0d65c0d4ba89644c74bf593a8f46"CRC64NVMEFULL_OBJECT76418d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/The Catholic University of Korea, Seoul St. Mary's Hospital.JPG2025-03-19T07:02:23.000Z"3e96fbca11f0c6d6c4e66475e67d5dbb"CRC64NVMEFULL_OBJECT66969d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD19-03-2025/Universitair Medisch Centrum Rotterdam.JPG2025-03-19T07:02:23.000Z"2963ab84a6f25edc8c052eda50238020"CRC64NVMEFULL_OBJECT68377d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1905_Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory_Nowakowski.png2025-12-29T05:06:16.000Z"cbd9911621485b0d750d5ce36f454f04"CRC64NVMEFULL_OBJECT1027090d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1917_Phase 2 Study of polatuzumab vedotin, zanubrutinib and rituximab (Pola-ZR)_Ren.png2025-12-18T09:53:41.000Z"a895bbc0667b5def8d185b1605ffdf4f"CRC64NVMEFULL_OBJECT1399856d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1938P_Anti_PD1_NSCLC_Liu.pdf2025-11-06T07:09:44.000Z"f2e105bbb4b0e0842aac2e41e49b6606"CRC64NVMEFULL_OBJECT2234415d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1946P_cMET_MYTX 011_NSCLC_ anti tumor activity across a broad spectrum NSCLC_Shum.pdf2025-10-24T05:54:09.000Z"61b83d096e3969f27c1b35bc49e71ca4"CRC64NVMEFULL_OBJECT366846d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1948P_cMET_Teliso V_NSCLC_Dose modifications in the LUMINOSITY trial_Mansfield.pdf2025-10-23T18:21:42.000Z"ba6e1f460714be96e8cc295daa07f260"CRC64NVMEFULL_OBJECT1416227d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1952P_TROP2_Sacituzumab Govitecan_mNSCLC_EVOKE 01 study_Felip.pdf2025-10-24T06:17:15.000Z"65b3196a564aa2587f9a2340cb198888"CRC64NVMEFULL_OBJECT533894d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1966_Efficacy and safety of loncastuximab tesirine and rituximab (Lonca-R)_Hsieh-Wong.png2026-01-03T17:05:32.000Z"c22a443424ad68c3aa8e26c04b3eccdd"CRC64NVMEFULL_OBJECT1001560d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD1st Bio.jpg2026-02-19T06:35:53.000Z"a22f2defb259f87ff66660acc8a81842"CRC64NVMEFULL_OBJECT39224d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2005_Patritumab deruxtecan (HER3-DXd)_Division of Oncology_advanced solid tumors_Ph2_TUXEDO-3__Patritumab deruxtecan (HER3-DXd_M.pdf2025-06-13T11:42:33.000Z"9e9d2d6091cbbc7985499b30a64c3d33-2"CRC64NVMEFULL_OBJECT9841226d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2023 AACR poster_ABL205_v2.pdf2025-08-07T06:37:16.000Z"8fca32b8c09461dabe4b6997aeb1a99a"CRC64NVMEFULL_OBJECT2014923d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2023P_Trop2_Dato-DXd_a NSCLC_Phase 1b Initial Safety Results_Spira.pdf2025-10-23T17:24:53.000Z"7320de97e8aaea9796243d232f52e9cd"CRC64NVMEFULL_OBJECT5123864d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2025_AACR-NCI-EORTC_QP101_final.pdf2025-11-10T07:14:36.000Z"497426c30528c6c64bcf1ea17c96e509"CRC64NVMEFULL_OBJECT2133502d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD203P.pdf2025-12-11T11:52:29.000Z"517c50cd9841c14b76bf9d69f0132761"CRC64NVMEFULL_OBJECT101308d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD204P.pdf2025-12-11T12:24:33.000Z"01dd90739409824a51e11637ba0bc364"CRC64NVMEFULL_OBJECT265867d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD208.jpg2026-03-03T14:34:14.000Z"a61a26b2b24200c68292f9b37c52343b"CRC64NVMEFULL_OBJECT340275d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2080eTiP_EGFR HER3_Iza-bren_Solid tumors_A phase 1-2a study_Florescu.jpg2025-10-23T07:02:44.000Z"6fd744757ef1ed8df727cda3b43d9e96"CRC64NVMEFULL_OBJECT3837284d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2081eTiP_B7-H3 CDH6_I-DXd + R-DXd_NSCLC_KEYMAKER-U01 Phase 2 Substudies 01H01I_Nadal.pdf2025-10-27T09:52:21.000Z"53fe312bf618e3e7e8a99f5742cf530d"CRC64NVMEFULL_OBJECT1595914d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2084_Phase 2 study of nivolumab for patients with meningiomas refractory to surgery and radiotherapy with immune-related response criteria_Sasaki.jpg2025-06-25T12:21:42.000Z"081b912778f58731aff4797f254986c1"CRC64NVMEFULL_OBJECT6620781d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD209.jpg2026-03-03T11:40:44.000Z"12eb6e8452210c2ae852ff452ecb7bbf"CRC64NVMEFULL_OBJECT313964d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD209.pptx2026-03-03T11:39:10.000Z"288df6ed0e3d9a157390264e7c24329c"CRC64NVMEFULL_OBJECT4579826d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2099P.jpg2025-10-21T11:11:34.000Z"0fef5693a9e988ffa334c496cdc2fb3d"CRC64NVMEFULL_OBJECT4363488d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD21-08-2025/2025-08-21T10:08:16.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0STANDARD21-08-2025/INSYS Therapeutics.JPG2025-08-21T10:08:16.000Z"5c61ec845117b6806547bbb3ef15aa89"CRC64NVMEFULL_OBJECT46891d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD21-08-2025/James Graham Brown Cancer Center.JPG2025-08-21T10:08:16.000Z"6aad1a27ce3e057d85162b5f684d5bfa"CRC64NVMEFULL_OBJECT42361d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD21-08-2025/Oslo University Hospital.JPG2025-08-21T10:08:16.000Z"7583bc65d9e87b8b951c604c5231a750"CRC64NVMEFULL_OBJECT34628d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD21-08-2025/Teva Branded Pharmaceutical Products R&D.JPG2025-08-21T10:08:16.000Z"b281e39585edc85cb1cc55affdb4d7a0"CRC64NVMEFULL_OBJECT36204d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD21-08-2025/[177Lu]Lu-NeoB.jpg2025-08-21T10:16:11.000Z"6282f30a83bb433cf2f67ba24b0ef41b"CRC64NVMEFULL_OBJECT36737d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2100P_Tislelizumab_GJC_RATIONAL_305_Moehler.pdf2025-10-31T10:58:12.000Z"2398ad73fcc745b6c388b6b903fccc54"CRC64NVMEFULL_OBJECT1433797d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2111P_Nivolumab_GEJ_Hisato Kawakami.pdf2025-10-31T11:32:53.000Z"c0eced2d32c2a054951586e04cea5157"CRC64NVMEFULL_OBJECT726002d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2115.jpeg2025-05-19T17:05:24.000Z"fcdbd643c3effdd762d85f66da3beb91"CRC64NVMEFULL_OBJECT2689529d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2124P_Sintilimab_ESCC_Linlin Wang.pdf2025-10-31T12:08:56.000Z"c342d74d6f13f61db7d97c4b8da19522"CRC64NVMEFULL_OBJECT475414d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2131.jpeg2025-05-13T06:27:51.000Z"580867b08c97c1f76a19d76f5d43f92b"CRC64NVMEFULL_OBJECT2712746d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2132.jpeg2025-05-19T17:02:48.000Z"621202b10a8ba9c2708b41ae699f21bf"CRC64NVMEFULL_OBJECT2298313d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2133.jpeg2025-05-08T07:02:09.000Z"5a0e4a24da98a00a79bb8d9bf137dba5"CRC64NVMEFULL_OBJECT2355496d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2134.jpeg2025-05-19T17:04:46.000Z"a8310e8e39eb0cbe4bbb8773da9c0846"CRC64NVMEFULL_OBJECT2818734d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2135P.jpg2025-10-21T11:43:55.000Z"3a878af741334b00ac46709e41eaf11a"CRC64NVMEFULL_OBJECT5439027d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2138.jpeg2025-05-16T13:16:11.000Z"eff50e4ff5321fe51372b5c7961e5aaa"CRC64NVMEFULL_OBJECT2874487d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2161_Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma_Duplan.png2026-01-03T14:13:13.000Z"eac2e1dc85ef2c80bd95989db3cbb989"CRC64NVMEFULL_OBJECT1770251d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2165P_Adebrelimab_GEJ_He.pdf2025-10-31T12:43:07.000Z"cffe0be77ef05a5775b61df400a44251"CRC64NVMEFULL_OBJECT259641d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2175P_HER2_T-DXd_Oesophagogastric cancer_DESTINY-Gastric06 study_Shen.jpg2025-10-24T13:19:35.000Z"28999b432f37859c852a322de5d3d632"CRC64NVMEFULL_OBJECT4781651d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2243.jpeg2025-05-08T07:40:54.000Z"617383b8ac04e86e7034b8e622964cd9"CRC64NVMEFULL_OBJECT2701693d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2243_Preclinical studies of BB-1709, a CD73-targeting ADC potentially suppresses tumor growth through dual mechanisms_Xia.jpg2025-05-23T12:17:36.000Z"bfe900fb72af40025f27f3bb3b5abb0d"CRC64NVMEFULL_OBJECT3083942d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2260_Impact of belantamab mafodotin containing regimens on renal function in patients_Lacerda.png2026-01-10T06:28:27.000Z"1f55815be7865db28c49f771e21ba9bb"CRC64NVMEFULL_OBJECT1241960d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2262_Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib_Hungria.png2026-01-10T05:47:14.000Z"4995bd251c758cafc2fbda347d14bc93"CRC64NVMEFULL_OBJECT1247334d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2264_Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide_Trudel.png2026-01-10T04:55:07.000Z"dd9ec4a3a7e36548b3b05e35c215f974"CRC64NVMEFULL_OBJECT1270061d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2265_Patients with Relapsed Refractory multiple myeloma_Mateos.png2026-01-10T04:54:58.000Z"48e2fcfc1b65172c679494048c1deb1b"CRC64NVMEFULL_OBJECT1134068d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2312_Tracking clonal dynamics, tolerance, and adverse events after CD45-ADC_Hayal.png2026-01-04T03:50:10.000Z"63dad240284ee0fa6d08e886271bb514"CRC64NVMEFULL_OBJECT2395480d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD236eP_FRα_LY4170156_Translational PKPD modelling_Pothuri.jpg2025-10-26T17:19:42.000Z"d4c886d734b5696ccb4111ea7c16ed6d"CRC64NVMEFULL_OBJECT4488226d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2376_Nivolumab_DLBCL_Long-term follow up of nivolumabipilimumab-primed immunotransplant in patients_NCT03305445_Wehmeyer.png2025-12-19T08:58:46.000Z"b8fdd7c7b3ba8e05007b071b6f5bfb8a"CRC64NVMEFULL_OBJECT1289352d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2390P_PSMA_177Lu PSMA 617_PSMAfore study_Herrmann.pdf2025-10-27T08:28:16.000Z"6cec60b408b807463ee855ab09d7a59c"CRC64NVMEFULL_OBJECT428745d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2391P_PSMA_177Lu PSMA 617 + olaparib_mCRPC_LuPARP Phase 1 trial_Sandhu .jpg2025-10-24T06:55:58.000Z"30464c87d86037d37663d6d7c8acc262"CRC64NVMEFULL_OBJECT4469905d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2394P_PSMA_177Lu PSMA 617 + Enzalutamide_mCRPC_ANZUP 1901 trial_Crumbaker.jpg2025-10-26T17:49:58.000Z"2029fce80a265ccc86cb9d23167a00e0"CRC64NVMEFULL_OBJECT3654688d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD24-04-2025/2025-04-24T11:02:06.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD24-04-2025/Asieris.JPG2025-04-24T11:02:06.000Z"59ef7c23ca5152d781af34270f453eb9"CRC64NVMEFULL_OBJECT44900d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD24-04-2025/ECOG.JPG2025-04-24T11:02:06.000Z"4fa4c878e7c0659f1723bb9a4aff1f4e"CRC64NVMEFULL_OBJECT46528d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD24-04-2025/Kowa.JPG2025-04-24T11:02:06.000Z"27f1f7cd1dc09603409f10fbe479f55f"CRC64NVMEFULL_OBJECT58771d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD241023-CD_The-Journey-of-ADC_Lessons-Learned-from-40-Years-of-Development.pdf2025-07-14T17:39:43.000Z"63168a4c400f47555aafac6d4ece3543-2"CRC64NVMEFULL_OBJECT9260320d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD241MO_Results from COSTAR lung cobolimab_dostarlimab_COSTAR_Enriqueta Felip.pdf2025-12-18T10:58:10.000Z"9b3ae95f71ac35853738708e4bb72f52"CRC64NVMEFULL_OBJECT1058454d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2421P_TROP2_sac TMT + Pembro_mCRPC_Phase 2 MK 2870 002 result_Ye.pdf2025-10-24T09:52:37.000Z"f8ef82b47e49eaa96f3599f8550f3343"CRC64NVMEFULL_OBJECT369517d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD243_A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors_Ho.jpg2025-06-13T12:58:20.000Z"3376260f3c9003aca698ed284e62e532"CRC64NVMEFULL_OBJECT8018836d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD247P_Adebrelimab_Pancreatic_Efficacy of adebrelimab with chidamide, gemcitabine, and S-1_Xiufeng Liu.pdf2025-12-18T13:42:31.000Z"88503ca80472d41b5e684bea14741f64"CRC64NVMEFULL_OBJECT662298d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD248_Safety and efficacy of ADG126 (an anti-CTLA-4 masking antibody) in combination with pembrolizumab Updated results of phase 1b2 study in advanced MSS CRC_Li.jpg2025-06-20T07:57:59.000Z"b0acf9e837ac9ba1fbbacbcca170ab5d"CRC64NVMEFULL_OBJECT3701838d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD25-04-2025 11/2025-04-25T14:12:44.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD25-04-2025 11/Precision Biologics.jpg2025-05-02T14:45:10.000Z"04a2d3666e99bd805a13c47c553895e1"CRC64NVMEFULL_OBJECT39157d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD25-04-2025 11/Qilu Pharmaceuticals.JPG2025-04-25T14:12:44.000Z"2d64d7e67e396307426b1450a0410a84"CRC64NVMEFULL_OBJECT54731d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD25-04-2025 11/TOAD Oncology.JPG2025-04-25T14:12:44.000Z"e38da94dc2e459f9cfd3710626b27e5b"CRC64NVMEFULL_OBJECT54918d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD25-04-2025 11/Taipei medical.JPG2025-04-25T14:12:44.000Z"097e85402284cdd7dfde6e82248b1c6d"CRC64NVMEFULL_OBJECT83027d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD25-04-2025 11/WPD Pharmaceutical.JPG2025-04-25T14:12:44.000Z"3c502d309ad302ff38095360d3fe89da"CRC64NVMEFULL_OBJECT46898d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD25-04-2025/2025-04-25T14:31:45.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD25-04-2025/Baylink Biosciences.jpg2025-04-25T14:31:45.000Z"6d1ae591abbdb64a8dce0066713f6abf"CRC64NVMEFULL_OBJECT46569d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD25-04-2025/WPD Pharmaceuticals.jpg2025-04-25T14:31:45.000Z"08767d8d994cc0c4f816f321c2bbd184"CRC64NVMEFULL_OBJECT45244d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2516TiP_PSMA_225Ac-PSMA-617_PSMA-positive_mCRPC_A phase 23 PSMAcTION trial_Emmett.pdf2025-10-23T11:40:40.000Z"5dfe24f86fa186c5a9a1fcf4b5927cc8"CRC64NVMEFULL_OBJECT309421d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD252P_Cemiplimab_Solid_Phase 1 Clinical Trial of BHV-1510, a Next-Generation_NCT06384807_Shiraj Sen.pdf2025-12-18T12:30:41.000Z"d3e2d49c0cb9109d7609febae77d695e"CRC64NVMEFULL_OBJECT1583057d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2536eTiP_PSMA_(Lu177) rosopatamab tetraxetan_mCRPC_ProstACT Phase 3 study_Merseburger.jpg2025-10-23T17:21:31.000Z"6fabb697f32e059a2c8dac12ba7561cf"CRC64NVMEFULL_OBJECT4440116d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2540eTiP_PSMA_177Lu-PSMA-617_mCRPC_FLEX-MRT Phase 2 trial in progress_Holzgreve.jpg2025-10-27T09:57:56.000Z"6de66137f04eb56abb22d0550543869b"CRC64NVMEFULL_OBJECT4296538d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2550 POSTER.jpg2025-12-18T12:00:34.000Z"25f33e9211cb2343407400f2dd919fdd"CRC64NVMEFULL_OBJECT244436d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD26 nov/2024-11-26T10:37:44.000Z"d41d8cd98f00b204e9800998ecf8427e"0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD26 nov/Alpha Tau Medical.png2026-02-05T14:03:04.000Z"9d6dace276f5b0285e5d9b9d79b607a6"CRC64NVMEFULL_OBJECT3552d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD26 nov/Crolll Gmbh.png2026-02-05T13:43:52.000Z"c844a5a32360bcee87d3107efe729037"CRC64NVMEFULL_OBJECT5010d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD26 nov/Everest Medicines.jpg2026-02-05T14:05:26.000Z"610f60e600bbc5fba4eabe3c9b126ecb"CRC64NVMEFULL_OBJECT6558d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD26 nov/Flare Therapeutics.png2026-02-05T14:02:09.000Z"1352c116ecefbfe70ee1dcb36549c3bf"CRC64NVMEFULL_OBJECT2927d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD26 nov/GI innovation.jpg2024-11-26T10:38:04.000Z"b2840031fc79b41f040567368579105a"44573d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD26 nov/Hangzhou Converd.png2026-02-05T14:00:48.000Z"d4c63e258b0a0a7cde793ddbae1070d8"CRC64NVMEFULL_OBJECT2292d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD26 nov/Hanmi Pharmaceutical.png2026-02-05T14:04:11.000Z"dd2bd8304ab22e400fecf3e36dc57201"CRC64NVMEFULL_OBJECT4848d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD26 nov/Kangabio.jpg2026-02-05T13:56:08.000Z"d7eaaef9a1e140de296702e1cf658a81"CRC64NVMEFULL_OBJECT6803d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD26 nov/Rondo Therapeutics.png2026-02-05T14:05:53.000Z"b33f7ae5ef4fff5168c754cdaabf55ce"CRC64NVMEFULL_OBJECT6377d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD26 nov/TJ.jpg2026-02-05T13:59:27.000Z"e06c3118276d10d85c07bb292d70ba48"CRC64NVMEFULL_OBJECT5187d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD26 nov/Zydus Lifesciences.png2026-02-09T10:58:15.000Z"f5a584144a4aadbdc319ce6e39ca38ed"CRC64NVMEFULL_OBJECT6834d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2600MO_Nivolumab_RC_Ignacio Duran.pdf2025-11-05T10:06:55.000Z"df2aef37aaf21f5bd9170c5f3d806932"CRC64NVMEFULL_OBJECT2344368d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2602P_Iparomlimab_RCC_Pei Dong.pdf2025-10-31T13:04:15.000Z"71f89e1adb4cd9242971701baaa74f6f"CRC64NVMEFULL_OBJECT681653d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2685O_nivolumab_alveolar soft-part sarcoma_N Hindi, S Strauss.pdf2025-11-05T06:42:42.000Z"12f8aff23641565d69f19278f39508ac"CRC64NVMEFULL_OBJECT833052d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2687MO_Nivolumab_STS_CONgTAtS_Peyraud.pdf2025-11-05T08:00:45.000Z"ab8b2b4bb44f5024f6f0834b42fb3bc1"CRC64NVMEFULL_OBJECT2243139d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2693.jpeg2025-05-16T08:31:59.000Z"40bebc66bba6667c026aba8f0a0e9e64"CRC64NVMEFULL_OBJECT2770721d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/2024-09-27T10:56:09.000Z"d41d8cd98f00b204e9800998ecf8427e"0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Abramson Cancer Center At Penn Medicine.JPG2024-09-27T10:59:29.000Z"2658c2d02af37e6362a8fcf8fbf8a659"64411d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Affiliated Hospital Of Nantong University.JPG2024-09-27T10:59:29.000Z"dfcd8b313d519319a91a0d50c814a315"66280d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Agensys.JPG2024-09-27T10:59:29.000Z"be2a44319bcdd1d02d43282f1675c6f7"41236d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Akeso Biopharma.JPG2024-09-27T10:59:29.000Z"1f65251de4cc2f75975c6c12bf3d52e0"48532d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Akso Biopharmaceutical.JPG2024-09-27T10:59:29.000Z"0d49b0f0bf581d216771648eb8db61ad"63771d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Alentis Therapeutics.JPG2024-09-27T10:59:29.000Z"4733f186f32f1e132f2e6e7cc5660c18"46653d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Asana Biosciences.JPG2024-09-27T10:59:29.000Z"fe248bbaa052b0fea9414b24afcc70de"61430d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Beijing Childrens Hospital.JPG2024-09-27T10:59:29.000Z"f4f919819c5db042c58561cd53b0dc2d"72589d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Beijing Kangkang Biotechnology.JPG2024-09-27T10:59:29.000Z"24f9cfa3744b698cce5ba8411e3cbe55"56148d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Beijing Mabworks Biotech.JPG2024-09-27T10:59:30.000Z"c96725378d86b2d4d7e1308b906d4cc6"75787d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Beijing Neoletix Biological Technology.JPG2024-09-27T10:59:30.000Z"a7cd17f017fc764a45a4a349fb1c8dc7"75311d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Bionecure Therapeutics.JPG2024-09-27T10:59:30.000Z"00dce04edcec73ea497b8396c7413278"41633d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Bioprocessing Technology Institute.JPG2024-09-27T10:59:30.000Z"cb9c6c2e2047b54fa1af103d90a3a5d3"47220d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Bioray Biopharmaceutical.JPG2024-09-27T10:59:30.000Z"f12c004e0f6fec8c84351e0274b49344"93705d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Bisichem.JPG2024-09-27T10:59:30.000Z"a5e91a440a3850535929f24a85b0ad6a"64332d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Boan Biotech.JPG2024-09-27T10:59:30.000Z"4debeee00bc35527ee9f09bf00e2b8d2"51968d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Brickbio.JPG2024-09-27T10:59:30.000Z"4195fa78f8e54aa0178e475659dce99c"47491d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Bristol Myers Squibb.JPG2024-09-27T10:59:30.000Z"abb5e5ba94a9920bd66d86ff258b44ee"34490d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Changhai Hospital.JPG2024-09-27T10:59:30.000Z"a4646b92b644a4783fc37c4b26c1dcb3"81247d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Children'S Oncology Group.JPG2024-09-27T10:59:30.000Z"5860b63022ce9552d362f824d24802fd"69280d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Chiome Bioscience.JPG2024-09-27T10:59:30.000Z"cefdd430652570d07aeb5e421cfb637a"62489d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Coherent Biopharma.JPG2024-09-27T10:59:30.000Z"f8158299f528d0ea5e927f828e1586c1"84170d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Cytomx Therapeutics.JPG2024-09-27T10:59:30.000Z"89290c60a195a09bde9f6a79b503b44b"38991d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Domantis.JPG2024-09-27T10:59:31.000Z"ef995dcfadeec8e44800cdc6dad31b89"43266d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Duke University.JPG2024-09-27T10:59:31.000Z"490c14f75429e206e2fedfb324b2f9c5"63025d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/EMD Serono.JPG2024-09-27T10:59:31.000Z"197db5b37650e0b54d76c27db6da02e9"69083d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Edisbiotech.JPG2024-09-27T10:59:31.000Z"66d1406751d2b176bba6e0ee3c9a3a96"52550d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Elevation Oncology.JPG2024-09-27T10:59:31.000Z"ba850a548e7ac390b20564a3d6ee8b57"50754d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Enliven Therapeutics.JPG2024-09-27T10:59:31.000Z"a001286d3898ab160ed84855c9322303"75907d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Erasmus Medical Center.JPG2024-09-27T10:59:31.000Z"70885851d841cd0de98c80e8b84e8eaa"69699d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Esperance Pharmaceuticals.JPG2024-09-27T10:59:31.000Z"f9077cc7212152fee45b021fd9ea37a6"54078d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/European Organisation For Research And Treatment Of Cancer.JPG2024-09-27T10:59:31.000Z"75b01c28499ecae3bd7ab22f0849349f"86692d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Femtogenix.JPG2024-09-27T10:59:32.000Z"c49ce9b6a6b872e3a502e861d288c9b3"65587d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Fondazione Irccs Istituto Nazionale Dei Tumori.JPG2024-09-27T10:59:32.000Z"f45f1ca9637bb9583b570786b8c031f7"55693d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Fondazione Italiana Linfomi - Ets.JPG2024-09-27T10:59:32.000Z"ddeffd380442c101f4cf3e1f0fe4d529"61362d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Fondazione Michelangelo.JPG2024-09-27T10:59:32.000Z"abdbaf4a219975d1f8ffd6ebeb3f0344"83923d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Fox Chase Cancer Center.JPG2024-09-27T10:59:32.000Z"b4e534ffb15b0a1828074d7db7e9ff93"103310d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Fred Hutchinson Cancer Center.JPG2024-09-27T10:59:32.000Z"f643f0ef3bf71ba056417dc3d6a1c987"60307d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Fudan University.JPG2024-09-27T10:59:32.000Z"4113396325b3827a30caf5c6bfdd08bd"110997d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Fundacian Para El Progreso De La Oncologa En Cantabria.JPG2024-09-27T10:59:32.000Z"4f13340e0d10213912aee768a14fb362"58444d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/G1 Therapeutics.JPG2024-09-27T10:59:32.000Z"75fdd5b8bcc8714921ef53d198e7ee7e"70194d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/GWT-TUD GMBH.JPG2024-09-27T10:59:33.000Z"3bb447eded1edbcbd26d0a5dc67c64d7"74160d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Ganymed Pharmaceuticals.JPG2024-10-25T07:15:28.000Z"73508caf3dacf767f954d3b60a2404a2"44236d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Genentech.JPG2024-09-27T10:59:32.000Z"6c2c55a8abe255bff8066d0a2de0210f"72105d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/German Breast Group.JPG2024-09-27T10:59:32.000Z"a70c0158385cd6b7f4da21e742f42b93"63120d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Gibson Oncology.JPG2024-09-27T10:59:32.000Z"6ef7336a74b842e86eb0653f1eea0435"51187d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Gilead Sciences.JPG2024-09-27T10:59:32.000Z"59308970e5424a14821fdb8401059352"43335d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Glykos.JPG2024-09-27T10:59:33.000Z"2a2715e0f44e9b44d55ac5b6afd6e61c"44846d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Gpcr Therapeutics.JPG2024-09-27T10:59:33.000Z"40a60a5ac602e2d3c13d59856b9501a6"68386d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Grupo Espanol De Linfomas Y Transplante Autologo De Medula Osea.JPG2024-09-27T10:59:33.000Z"bc6a38f529b29a18d4439a60d0967bb3"78934d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Grupo Espanol De Tumores Neuroendocrinos.JPG2024-09-27T10:59:33.000Z"e1b46ff9f38c80c568398cb4a276e63b"52666d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Guangdong Zhongsheng Pharmaceutical.JPG2024-09-27T10:59:33.000Z"932202b1440d4f4b219272b0f027015a"77508d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Gundersen Medical Foundation.JPG2024-09-27T10:59:33.000Z"8569cbdb3d02525fab18c29c77af057f"74360d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/H. Lee Moffitt Cancer Center And Research Institute.JPG2024-09-27T10:59:33.000Z"fd7dceca42e5225c277545088ba30464"59157d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Hangzhou Sumgen Biotech.JPG2024-09-27T10:59:33.000Z"1bc1f501ab8eb2ea1b2c6be3f17f827c"49233d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Hangzhou Zhongmei Huadong Pharmaceutical.JPG2024-09-27T10:59:33.000Z"6795d993d8434114a8dc660eaefa6b94"78458d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Harpoon Therapeutics.JPG2024-09-27T10:59:33.000Z"effaf8593b2393c114834b5151b50d26"53082d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Henan Cancer Hospital.JPG2024-09-27T10:59:33.000Z"97df1bfe5027bbc92a0b4fa200eeac81"61061d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Henry Ford Health System.JPG2024-09-27T10:59:34.000Z"880e6e595252b14b30f61fa3a93bdd07"104841d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/High Tech Of Atom.JPG2024-09-27T10:59:34.000Z"955e0f37968dcf96203ca63440477ae9"47676d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Hospital Clinic Of Barcelona.JPG2024-09-27T10:59:34.000Z"55f369cbeaa8cd7e781ed00c63f26919"83411d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Hospital Regional De Alta Especialidad Del Bajio.JPG2024-09-27T10:59:34.000Z"5777af60f6917b59c1a73bc01c942fab"84962d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Ibex Biosciences.JPG2024-09-27T10:59:34.000Z"b5d1ee39d6be9871233999835487efb0"68636d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Icahn School Of Medicine At Mount Sinai.JPG2024-09-27T10:59:34.000Z"25a0fec0b0f419fb570624153b1cc60f"74273d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Immunesensor Therapeutics.JPG2024-09-27T10:59:34.000Z"4dcfb593a1ba08bb65c45f5f0948571f"46147d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Indiana University School Of Medicine.JPG2024-09-27T10:59:34.000Z"722dd4528a5a01d8dd564d1fddfd3763"57567d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Indiana University.JPG2024-09-27T10:59:34.000Z"53e12c8a56ff2b99e47c48e325e74718"46585d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Innate Pharma.JPG2024-09-27T10:59:34.000Z"32e6d0a1f359ef48903402eced5d9e91"54153d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Innolakebio.JPG2024-09-27T10:59:34.000Z"781d6cd37a33cdac6828ea9e3c6aab8f"40313d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Institut Paoli-Calmettes.JPG2024-09-27T10:59:34.000Z"e1364c408670bd847e2e5b10a3aa97c0"61694d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Inxmed.JPG2024-09-27T10:59:34.000Z"9ca0a41158717496c2806d6e7507934c"54304d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Iprogen.JPG2024-09-27T10:59:34.000Z"d6f94a794c7bd0475793801c88a07535"62932d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Ipsen.JPG2024-09-27T10:59:34.000Z"9a3351f481ae574824ea779631e937cf"63213d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Iwate Medical University.JPG2024-09-27T10:59:35.000Z"e4674bcd467dc9f282f9e7b57d4f5c46"66954d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Jonsson Comprehensive Cancer Center.JPG2024-09-27T10:59:35.000Z"ffd738103576a4fe56153bfccc837bd7"80206d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Jules Bordet Institute.JPG2024-09-27T10:59:35.000Z"3bd87154b507f5c51c00ff29fb68bf95"40399d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Karyopharm Therapeutics.JPG2024-09-27T10:59:35.000Z"093b29642d64e235ba2d47639f78b311"48991d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Keymed Biosciences.JPG2024-09-27T10:59:35.000Z"e6b6f719c736acd820a5cbdc134ab1cd"76214d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Klus Pharma.JPG2024-09-27T10:59:35.000Z"8e43032affbd403d1c68c07b2e26dfb0"53455d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Lantern Pharma.JPG2024-09-27T10:59:35.000Z"6333cde5e6922d38ed3a194552d80653"44138d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Lantheus.JPG2024-09-27T10:59:35.000Z"0dbf9ce812d9c16dfc4d6fb55392695b"38426d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Ligachem Biosciences.JPG2024-09-27T10:59:35.000Z"a59e2cd2398a2c397f04904eb01844fe"39326d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Lls Pedal Initiative.JPG2024-09-27T10:59:35.000Z"0854c7b6a1a990e4d4053d1525048d73"50933d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Luzsana Biotechnology.JPG2024-09-27T10:59:35.000Z"61aac9865459246c7ca5660994a81ace"56416d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Mabion.JPG2024-09-27T10:59:35.000Z"998755bd1911b9c8d46d84f05355cbd0"39265d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Mablink Bioscience.JPG2024-09-27T10:59:35.000Z"c024cfb3e47c1c84f19ef1805dc8b5cb"42179d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Medarex.JPG2024-09-27T10:59:35.000Z"f513f6fb45ee1831bbd9d2db73a442a1"59448d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Mediapharma.JPG2024-09-27T10:59:35.000Z"bb18a80264a3eba9985b788288944263"52700d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Medical College Of Wisconsin.JPG2024-09-27T10:59:36.000Z"e4b521f5c47b38318ddce296b7f175c4"86564d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Medsir.JPG2024-09-27T10:59:36.000Z"dd5e872f054a477960bc0bf9351dce9b"52806d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Memorial Sloan Kettering Cancer Center.JPG2024-09-27T10:59:36.000Z"c7fd1eefba6b378f2dc8f6963bbc5706"47735d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Minghui Pharmaceutical.JPG2024-09-27T10:59:36.000Z"8fb253535d9bf5df6013c28e5b23af33"66806d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Mirati Therapeutics.JPG2024-09-27T10:59:36.000Z"145773f1c6db96dff7e89e54f254f778"46160d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Multicell Technologies (2).JPG2024-09-27T10:59:36.000Z"62415d094c84c70d369bad9eca8defb0"56816d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Multicell Technologies.JPG2024-09-27T10:59:36.000Z"85fd99fc221b2c2946071b74514cb548"51224d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/National Taiwan University Hospital.JPG2024-09-27T10:59:36.000Z"6e41a3582c08e007d602bb64bb3bc097"59998d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Nectin Therapeutic.JPG2024-09-27T10:59:36.000Z"60387eb3f539eb4ea785b9b2cc71110e"37944d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/New York Medical College.JPG2024-09-27T10:59:36.000Z"8280dc52c44ecb6ff1e7458ec2a8d27b"128955d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Newbio Therapeutics.JPG2024-09-27T10:59:36.000Z"af1a5317eb611c3e988dc0f2ecfbe2eb"54302d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Nordic Lymphoma Group.JPG2024-09-27T10:59:36.000Z"17ed54b88a44d1e0cfe458412bf058a2"67773d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Northwestern University.JPG2024-09-27T10:59:36.000Z"772c616e6260fc1c6b477ec26df90e9c"121183d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Novacyte Therapeutics.JPG2024-09-27T10:59:36.000Z"5a0d031d409bf7d39e549933634f3d7a"56002d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Novartis.JPG2024-09-27T10:59:36.000Z"75cfb1dd67d9544960a6bdca6653124f"47115d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Novatim Immune Therapeutics.JPG2024-09-27T10:59:36.000Z"dd19f1754b15671babdb518efc731e36"42175d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Nsabp Foundation.JPG2024-09-27T10:59:37.000Z"2a35e29848c8368ce831d921f7e1733b"73071d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Ogd2 Pharma.JPG2024-09-27T10:59:37.000Z"e97063090c8be56f0b0620bc585cfddd"43815d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Ohio State University Comprehensive Cancer Center.JPG2024-09-27T10:59:37.000Z"3458b84dd0fb37bf52da11d9d247f78f"62320d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Ohsu Knight Cancer Institute.JPG2024-09-27T10:59:37.000Z"90cd02506c7e3a0f25da623e7e5fc2ab"71096d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Oncoc4.JPG2024-09-27T10:59:37.000Z"f53268a02355260ec476ebb58baca474"37196d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Oncology Institute Of Southern Switzerland.JPG2024-09-27T10:59:37.000Z"c6f8e02878e539236ef59379750d85df"50684d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Oncomatryx Biopharma.JPG2024-09-27T10:59:37.000Z"e8adeeea2cf3181ae681eefb94d0a2ba"53804d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Open Innovation Partners.JPG2024-09-27T10:59:37.000Z"d9482f4246a7d9feda8aff4c950f6c2c"41603d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Peak Bio.JPG2024-09-27T10:59:37.000Z"6e56e1ce0e87b074e519c30399ec7daa"46508d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Peking Union Medical College.JPG2024-09-27T10:59:37.000Z"8264678b89aa71714aa35e0435c5b7f6"65630d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Peking University.JPG2024-09-27T10:59:37.000Z"9d90ebae482ea03d4e6cdb79fd496e82"74308d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Pethema Foundation.JPG2024-09-27T10:59:37.000Z"aebc6330e9969012fc202b38d76a9bdd"44335d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Pinotbio.JPG2024-09-27T10:59:37.000Z"b242d596a69b72bbb4b06b8a4183caaf"47023d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Precisemab Biotech.JPG2024-09-27T10:59:37.000Z"9d20ef732bddfb11b61753b2458eb5f5"41285d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Princess Maxima Center For Pediatric Oncology.JPG2024-09-27T10:59:37.000Z"7ee96b6a299bcf32fc4c060a4397f44a"73791d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Pyxis Oncology.JPG2024-09-27T10:59:37.000Z"e40282770edd9460a8e87c9c62d05659"75377d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Qilu Hospital Of Shandong University.JPG2024-09-27T10:59:37.000Z"692adbcd74aed38ee51c582b23fe7df4"65344d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Renji Hospital.JPG2024-09-27T10:59:38.000Z"a5adbb616d02db41f1a1cdda0981d16e"104804d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Russian Academy Of Sciences.JPG2024-09-27T10:59:38.000Z"863d02dc31d0b1e07a531293aed3a38b"98995d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Salubrisbio.JPG2024-09-27T10:59:38.000Z"a5c09c9a5917f60a0c1a063db72fb16a"45910d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Second Affiliated Hospital Of Soochow University.JPG2024-09-27T10:59:38.000Z"814d51f63a14ad125da9a06912c6dd09"100404d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Sensei Biotherapeutics.JPG2024-09-27T10:59:38.000Z"8b779e7185cb7cc8875da1561123983b"42938d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Seoul National University College Of Medicine.JPG2024-09-27T10:59:38.000Z"f98eee7c0b5238d1c854a25fd0e66b65"49762d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Seoul National University Hospital.JPG2024-09-27T10:59:38.000Z"0c4bf2a73d148117634c59edf0ebbea3"77641d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shaare Zedek Medical Center.JPG2024-09-27T10:59:38.000Z"ba25500969e7a6f102df9858ef333f04"79551d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shanghai East Hospital.JPG2024-09-27T10:59:38.000Z"594d9a3eff364ea8fafdfc55e23d0dd9"103347d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shanghai Fudan-Zhangjiang Bio-Pharmaceutical.JPG2024-09-27T10:59:38.000Z"899cac4dfde904df25c1258d096d82bd"70850d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shanghai Hansoh Biomedical.JPG2024-09-27T10:59:38.000Z"fcdded85d1c2cdca8e46d0fb9403f699"54447d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shanghai Hengrui Pharmaceutical.JPG2024-09-27T10:59:38.000Z"e1b10acfa9f75142000753b142b9133d"80061d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shanghai Huaota Biopharmaceutical.JPG2024-09-27T10:59:38.000Z"9a92ba416bdeb4e98a7820bb485849eb"58179d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shanghai Institute Of Materia Medica.JPG2024-09-27T10:59:39.000Z"5af3e1c46eb230f707bb252ed7261f11"61957d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shanghai Jiao Tong University School Of Medicine.JPG2024-09-27T10:59:39.000Z"9e78eca8e1dd3b380f621be7faf4160b"81993d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shanghai Junshi Biosciences.JPG2024-09-27T10:59:39.000Z"84e890572f630462a4488947fd0e2dd8"66969d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shanghai Miracogen.JPG2024-09-27T10:59:39.000Z"b29e2afdc353dd53661ab106a19d7e0f"37596d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shanghai Pharmaceuticals Holding.JPG2024-09-27T10:59:39.000Z"3ea1ac9a3d0d109ad8e3b311ac35fade"79164d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shanghai Pulmonary Hospital.JPG2024-09-27T10:59:39.000Z"5b1ba4ca6b5d3a9193f24cdcc2909e08"97566d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Shanghai Zhongshan Hospital.JPG2024-09-27T10:59:39.000Z"ccf62e184b2a5d381cc7db63536db8ab"65698d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Solti Breast Cancer Research Group.JPG2024-09-27T10:59:39.000Z"8bf66de4db07d4de89344721afa9e022"34777d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Stemcentrx.JPG2024-09-27T10:59:39.000Z"0667fb89a1a34b188417a619dc829c69"61932d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Strata Oncology.JPG2024-09-27T10:59:39.000Z"5028fb8b7b0cb01c42049f90068c1af8"56163d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Stromatis Pharma.JPG2024-09-27T10:59:39.000Z"b59729b0dc85cc13254683b0f031c935"39450d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Sun Pharma Advanced Research Co.JPG2024-09-27T10:59:39.000Z"470e5d7298a5e83afb40be8f48f1879c"40619d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Sutro Biopharma.JPG2024-09-27T10:59:39.000Z"80f40d481dd66b5264dbd6e0c92cdbfa"55975d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Suzhou Suncadia Biopharmaceuticals.JPG2024-09-27T10:59:39.000Z"b223cbf69ce3c5f296e312a5bbdde062"62398d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Swog Cancer Research Network.JPG2024-09-27T10:59:40.000Z"b53a5c18528f994209398ad27bf1aa81"80866d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Symphogen.JPG2024-09-27T10:59:40.000Z"616b237a11fe2f4d44b53410641cb230"52256d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Syndivia.JPG2024-09-27T10:59:40.000Z"e6e5052f08f20bff264323fb35689968"37051d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Synthis Therapeutics.JPG2024-09-27T10:59:40.000Z"419fda3e73dd6a9b2c2227113177ad6e"47487d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Tacalyx.JPG2024-09-27T10:59:40.000Z"c240d910ff5f598c5060993033b59f6a"57072d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Tagworks Pharmaceuticals.JPG2024-09-27T10:59:40.000Z"fee3e90099ca1a0adc6693b40ec4d9d7"61155d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Takeda.JPG2024-09-27T10:59:40.000Z"212d9d295d66e1f034e869071e690fc3"63725d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Tanabe Research Laboratories.JPG2024-09-27T10:59:40.000Z"3a5b07765432279bb7ccccc0cfbb9633"101096d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Targinta.JPG2024-09-27T10:59:40.000Z"620bc6c906e567e2b8cea3325c5c5852"55198d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Temple University.JPG2024-09-27T10:59:40.000Z"6aa7496047e957dda8c5cac8697a66b9"59530d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Texas A&M University Health Science Center.JPG2024-09-27T10:59:40.000Z"f67876179182ce270eb9f38e123a4ca1"65197d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Tg Therapeutics.JPG2024-09-27T10:59:40.000Z"9fbe43fe43af2abe84e2a737ee35a59f"42334d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Tharimmune.JPG2024-09-27T10:59:40.000Z"49bca3e83c10ec569add533b738a388b"52046d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School.JPG2024-09-27T10:59:40.000Z"6098faa4e250901d273c5aec84013938"102964d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/The First Affiliated Hospital Of Soochow University.JPG2024-09-27T10:59:40.000Z"814d51f63a14ad125da9a06912c6dd09"100404d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/The First Affiliated Hospital Of Zhengzhou University.JPG2024-09-27T10:59:40.000Z"fc16aebc8d3fe13043357570a0143cee"95008d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/The Lymphoma Academic Research Organisation.JPG2024-09-27T10:59:41.000Z"21c8b3dbb802542e9842fc5bd5ed54cb"50283d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/The Netherlands Cancer Institute.JPG2024-09-27T10:59:41.000Z"1285a4827bf52242cdb531f5df8d2995"78410d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/The Thai Lymphoma Study Group.JPG2024-09-27T10:59:41.000Z"ac1b28aa447acbdcfb596867ba4b8289"63614d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/The University Of New South Wales.JPG2024-09-27T10:59:41.000Z"73df94d1dbd5a38312010f983c8bd960"68164d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Theragen Bio.JPG2024-09-27T10:59:41.000Z"4bdaf71ec26bd56ea714ec0285a556c9"45719d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Tianjin Medical University Second Hospital.JPG2024-09-27T10:59:41.000Z"9e849e59b9ea627cb602afe3d6b69691"61247d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Tot Biopharm.JPG2024-09-27T10:59:41.000Z"638c7e7af5498014913e304f1d1f2cd2"65766d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Transcenta Biopharma.JPG2024-09-27T10:59:41.000Z"dda57e700ae99d5aec984bc6df0e5e14"77517d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Translational Breast Cancer Research Consortium.JPG2024-09-27T10:59:41.000Z"f24b80f48b521e49d0e506e1eb5c8405"46532d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Trio Pharmaceuticals.JPG2024-09-27T10:59:41.000Z"edb66b51469a39a10f3c68eaf67605e0"68359d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Triphase Accelerator Corporation.JPG2024-09-27T10:59:41.000Z"938938a110484100300a11647d459e91"55909d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Tsd Life Sciences.JPG2024-09-27T10:59:41.000Z"2af453b7fa7667c1c25b803a800536de"49624d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Turning Point Therapeutics.JPG2024-09-27T10:59:41.000Z"097d9d7d5e9c280451ab702f3791d4cf"67435d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Unc Lineberger Comprehensive Cancer Center.JPG2024-09-27T10:59:41.000Z"376f4980b4fe3195c55abd9a7c6ee09e"79023d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Health Network.JPG2024-09-27T10:59:42.000Z"046b34d9d7305f8d20ea2f3a790966be"55898d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Hospital Carl Gustav Carus.JPG2024-09-27T10:59:42.000Z"33bad1e13f745be8ad0245a81870e07b"56297d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Arizona.JPG2024-09-27T10:59:42.000Z"7843cef95449c2e65ee7155e38dde25d"74791d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Birmingham.JPG2024-09-27T10:59:42.000Z"e091f3c49c0151a871898cc282471704"102376d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Colorado.JPG2024-09-27T10:59:42.000Z"30ad0791e798936e698c774ef58404ed"69467d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Kansas Medical Center.JPG2024-09-27T10:59:42.000Z"633f3b4d5f427d55f6a6d1c835f05f10"74364d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Miami.JPG2024-09-27T10:59:42.000Z"f5556f571029b96bf749fc9a0824329e"52590d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Michigan Rogel Cancer Center.JPG2024-09-27T10:59:42.000Z"dcef65ea5fd9c5282af5059ba71ec9ec"71296d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Modena And Reggio Emilia.JPG2024-09-27T10:59:42.000Z"6966991306c460176edac2749158387f"75133d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Oklahoma.JPG2024-09-27T10:59:42.000Z"ba79286584fea270086238cf225daf23"51642d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Pennsylvania.JPG2024-09-27T10:59:42.000Z"26e30ea56507e4e60a3d4edd07d94d39"73692d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Rochester.JPG2024-09-27T10:59:42.000Z"0bfb90cd87e4510303172646f38bc2c6"96378d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Saskatchewan.JPG2024-09-27T10:59:42.000Z"7e96b733bfff647ec5875c1c414d367a"72326d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Southampton.JPG2024-09-27T10:59:42.000Z"98e67fb99f43801c9b040ca94493db42"86471d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Strasbourg.JPG2024-09-27T10:59:42.000Z"ff288a51b86bbf62f3ed2590f203bb84"43733d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Texas Southwestern Medical Center.JPG2024-09-27T10:59:42.000Z"e5903a8fe71905a08e0e5776801476a5"92997d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Virginia.JPG2024-09-27T10:59:42.000Z"0f6758e03bd371b5ed04c2beeea38122"93730d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University Of Wisconsin.JPG2024-09-27T10:59:42.000Z"3d5e522d8ff722dc309e413c34ecda5c"101173d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University of Science and Technology of China.JPG2024-09-27T10:59:42.000Z"682aa01434d04560bd4db92f91ef92a0"86056d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/University of Utah.JPG2024-09-27T10:59:42.000Z"1dc40060404e33c0ad847b4443f9c61c"60006d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Universitätsklinikum Hamburg-Eppendorf.JPG2024-09-27T10:59:41.000Z"04de13e9ada7ae221b3c7758f57eb7a9"71646d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Vasgene Therapeutics.JPG2024-09-27T10:59:43.000Z"04018632d96157f527352169e6dc2a87"63988d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Versailles Hospital.JPG2024-09-27T10:59:43.000Z"f31df6449fc55964925ae68c4e3085f7"65567d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Virginia Commonwealth University.JPG2024-09-27T10:59:43.000Z"99168383f8c233ffb0f0a59dc175a9b8"92164d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Wake Forest University Health Sciences.JPG2024-09-27T10:59:43.000Z"a79b3fda8fa445986b44a08769052a29"71630d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Weill Medical College Of Cornell University.JPG2024-09-27T10:59:43.000Z"8d0e4f4b9ea76b417d5c01cc9b732e8c"91811d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/West China Hospital.JPG2024-09-27T10:59:43.000Z"b945728aab7d4ff60b8889442f8b2c60"60063d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/West German Study Group.JPG2024-09-27T10:59:43.000Z"70b76b1e43c835ddc3b5459a3076879e"57350d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Western Regional Medical Center.JPG2024-09-27T10:59:43.000Z"fc2e4c9334e94daa8ab91913f9c7b43c"67114d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Xiangya Hospital Of Central South University.JPG2024-09-27T10:59:43.000Z"b4828bc264835ece71f11b3a0b33b8c3"91065d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Xijing Hospital.JPG2024-09-27T10:59:43.000Z"7fd122378ffebe16c401ffde99216f8d"44722d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Xuanzhu Biopharmaceutical.JPG2024-09-27T10:59:44.000Z"072b1618e7935fb0a0f2c1b9fab20395"71538d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Zhejiang Cancer Hospital.JPG2024-09-27T10:59:44.000Z"ded242175761a6b63841f556e745e534"88928d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Zhejiang Medicine.JPG2024-09-27T10:59:44.000Z"e7d1a7700aaad5d99e40bb03152e1d20"63694d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/Zhejiang Teruisi Biopharmaceutical.JPG2024-09-27T10:59:44.000Z"e7a6203059f2f10213f54bb3c008fee0"61197d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/acea pharma.JPG2024-09-27T10:59:29.000Z"e50b65dd69c22b7025b14b171cdabc7a"62686d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/canadian cancer trials group.JPG2024-09-27T10:59:30.000Z"a9f1cfb85b929249204c87edfb0c66d8"45758d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/children hospital of phildelphia.JPG2024-09-27T10:59:30.000Z"9b7758ff79947da3b22c43d84c3b4ae9"66611d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/chu caen normandie.JPG2024-09-27T10:59:30.000Z"a651988e72b164532e731cff9ba42a6b"73030d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/crispr.JPG2024-09-27T10:59:30.000Z"c5331d4deeb554a85541eb2e3eea8e96"49842d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/emory.JPG2024-09-27T10:59:31.000Z"e5b4bcebb90715b1ffbfd6dbd95f67bc"65374d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/evexta bio.JPG2024-09-27T10:59:31.000Z"80c8c37a367e04179bfd97a6c5459df0"45505d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/medstar health.JPG2024-09-27T10:59:36.000Z"eaae742ae738185553c025dfa6321712"57410d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/new 27 sept 2024/2024-09-27T13:27:07.000Z"d41d8cd98f00b204e9800998ecf8427e"0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/new 27 sept 2024/Immunomedics.jpg2024-09-27T13:33:12.000Z"5fecbb210e49522f1cd27550cbea395b"69507d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/new 27 sept 2024/Kirilys Therapeutics.jpg2024-09-27T13:27:32.000Z"716a0ddc920fd1d833bfa4a0b720217c"55172d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/new 27 sept 2024/Mabcare Therapeutics.jpg2024-09-27T13:27:32.000Z"0f386d6a8c424d002eb65da21861f0e7"80419d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/unicancer.JPG2024-09-27T10:59:41.000Z"33864713b7b312eb938be06ecb67de6a"49735d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/varian.JPG2024-09-27T10:59:43.000Z"e2468cd3944ff403eea56d584b859e84"35170d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/velavigo.JPG2024-09-27T10:59:43.000Z"fa8686b552461694341b221ba41e02f8"58086d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/xiling lab.JPG2024-09-27T10:59:43.000Z"e15d3903bbc7e204ab766dea35e76b92"46238d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/zhejian provincial people hospital, hangzhou medical college.JPG2024-09-27T10:59:44.000Z"2e143f70cb366428cb147b6bd80d38c7"111727d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 SEPT 2024/zhejiang provincial peoples hospital.JPG2024-09-27T10:59:44.000Z"cf05d779efccc21a9976df32e6025a21"79593d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /2024-11-27T14:20:07.000Z"d41d8cd98f00b204e9800998ecf8427e"0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /Allink.jpg2024-12-03T14:12:18.000Z"908b9b99f27bae228ca8d9a7ca411743"41930d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /British Columbia Cancer Agency.png2026-03-18T10:33:50.000Z"408b897d53b6b92a59d695f397b9a567"CRC64NVMEFULL_OBJECT4229d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /Caedo Oncology.png2026-03-18T14:00:31.000Z"14c3ad62ec1ff2b955e28a9d4180d877"CRC64NVMEFULL_OBJECT3453d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /Fondazione Del Piemonte Per L'oncologia.jpg2024-11-29T13:05:14.000Z"ba2e115d671755004fde366246a4120b"54714d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /Genemedicine.jpg2024-12-11T12:06:51.000Z"3d0652cb79ed7588a0bc63173acdc7f7"42607d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /KU Leuven.jpg2024-11-27T14:20:29.000Z"0c4b957465304e990698bda9bf53809a"64375d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /Stanford University School of Medicine.jpg2026-03-18T12:32:31.000Z"5fd67e042a4f514fa72b85bea741e854"CRC64NVMEFULL_OBJECT12817d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /Stichting European Myeloma Network.jpg2024-12-09T09:46:26.000Z"57eb2c32368bb7cfed17aa3ffd6fff95"77653d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /Sungkyunkwan University.jpg2024-12-04T13:26:47.000Z"6e2469d688d5f1e5f9cfeacc788f0a6c"52713d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /Telix Pharmaceuticals.png2026-03-18T13:36:13.000Z"86498dadcb5d729882d2a561c53a2298"CRC64NVMEFULL_OBJECT5053d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /University of Colorado Anschutz Medical Campus.jpg2026-03-18T12:43:41.000Z"ceb2ba3c73742404bc5b2f589eb09882"CRC64NVMEFULL_OBJECT195800STANDARD27 nov /University of Ioannina.png2026-03-18T09:33:24.000Z"f290c024bb98bf0f07943f3891df82cb"CRC64NVMEFULL_OBJECT8826d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /Universität Stuttgart.png2026-03-18T11:37:54.000Z"6b61ea32209bc4058b2ecc0372a8d203"CRC64NVMEFULL_OBJECT5931d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27 nov /Yangzhou University.jpg2026-03-18T11:21:51.000Z"30328a7cd36718c3c1ce5f2ecdce9bb6"CRC64NVMEFULL_OBJECT9118d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27-03-2025/2025-03-27T10:38:21.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27-03-2025/Cantargia.JPG2025-03-27T10:38:21.000Z"298a158fc974c795d0e3566942f6b597"CRC64NVMEFULL_OBJECT43641d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27-03-2025/Chengdu Kanghong Biotech.JPG2025-03-27T10:38:21.000Z"a07014ff9a695b31a4e865ead967a44d"CRC64NVMEFULL_OBJECT50995d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2706P_Nivo_Ipili_STC_Jeffrey.pdf2025-10-31T13:29:25.000Z"ecce0c7fa9db5d71bb8f652eaffc91b5"CRC64NVMEFULL_OBJECT377084d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2743TiP_uPARAP_ADCE-D01_m u Soft Tissue Sarcoma_ Phase 12 Study_Schöffski.pdf2025-10-22T12:16:06.000Z"72a1f1bd177528314e216371f9c08a67"CRC64NVMEFULL_OBJECT1425114d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD27570_PDL1_SCLC_Wermke.pdf2025-11-05T09:06:10.000Z"4a01ba57a79a045a820bc7b7283508a4"CRC64NVMEFULL_OBJECT845540STANDARD275MO_Nivolumab_HCC_Overall efficacy outcomes of nivolumab_CheckMate 9DW_Thomas Yau.pdf2025-12-17T07:58:18.000Z"f821614e6655d9b79981eb24c6b93ebd"CRC64NVMEFULL_OBJECT256561d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2761O_Durvalumab_SCLC_Furqan.pdf2025-11-06T09:41:29.000Z"016393cf94909218713cef15dd450a81"CRC64NVMEFULL_OBJECT614885d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2770P_Adebrelimab_ES-SCLC_Yanbin Zhao.pdf2025-10-31T13:54:49.000Z"d2fe49b5747f146ab7eec94dbfb45117"CRC64NVMEFULL_OBJECT634577d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2780P_TME_BL0020_aSolid tumors_Phase 1 study result_Wang.jpg2025-10-27T05:49:56.000Z"dfb0c6a80e26264a123425fb93b8865b"CRC64NVMEFULL_OBJECT4194655d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD278P_Durvalumab_Randomized phase 2 trial of neoadjuvant gemcitabine-cisplatin (GemCis)_DEBATE_Changhoon.pdf2025-12-17T13:32:15.000Z"dc241f4cdae1af0f8ad2c752ff105e16"CRC64NVMEFULL_OBJECT1372433d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2792TiP_B7-H3 DLL3_Gocatamig + I-DxD_rr es SCLC_A phase 1b2 study_ Sun.pdf2025-10-23T13:07:10.000Z"ee3206576fb7f2e8e70c07479bdcb0fe"CRC64NVMEFULL_OBJECT1148583d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2798eTiP_SSTR2_[177Lu]Lu-DOTA-TATE_es SCLC_ Phase IbII study_Ares.pdf2025-10-23T17:31:21.000Z"005b6f1d4ebaefb14bb0643ab6501f70"CRC64NVMEFULL_OBJECT189196d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD279P.pdf2025-12-12T12:32:05.000Z"6eefb0328745e11a2c2d7ba7bec0808d"CRC64NVMEFULL_OBJECT78352d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2863.jpeg2025-05-16T13:26:59.000Z"5812e9b7a36b25b6de22e9fbc92d4395"CRC64NVMEFULL_OBJECT2452739d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2863.png2025-07-15T14:09:36.000Z"49cc8aec732f27e96f875499cf3e6ae6"CRC64NVMEFULL_OBJECT2618131d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2868.jpeg2025-05-12T13:04:20.000Z"eed255205d076097a28a11af99942e43"CRC64NVMEFULL_OBJECT2409564d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2869_DXC014, a novel bispecific ADC targeting B7-H3 and PSMA, demonstrates favorable antitumor efficacy and safety profiles in preclinical evaluations_Guo.jpeg2025-05-16T04:23:19.000Z"2344fd2ba0c49eb4ec27c3b5ea8ed033"CRC64NVMEFULL_OBJECT2318965d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD286_Tislelizumab_GC_TERRIFIC_Wei.pdf2026-01-20T08:06:55.000Z"04d8ccdd89df4591814eb9409d791396"CRC64NVMEFULL_OBJECT2129815d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2871.jpeg2025-05-13T07:01:39.000Z"9f75e261dbbcdd47a9fd43ddd0888ebe"CRC64NVMEFULL_OBJECT2611288d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2872.jpeg2025-05-13T07:16:13.000Z"bd0e5f3b39a399d4ea35bfa2c1f51153"CRC64NVMEFULL_OBJECT2592659d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2873.jpeg2025-05-13T13:16:00.000Z"704e6caf43e3c3bef486005907e1db09"CRC64NVMEFULL_OBJECT2679153d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2876.jpeg2025-05-19T17:38:30.000Z"b95a9d45769f2bd9bef85244f8b51002"CRC64NVMEFULL_OBJECT2243142d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2877_MRG007 a cadherin 17-targeted, glycan-linked, exatecan-based antibody-drug conjugate, demonstrated potent anti-tumor activity and a good safety profile in preclinical studies_Zeng.jpeg2025-05-15T06:03:23.000Z"86a0ab8203ce794d6df6a42a9a922a2b"CRC64NVMEFULL_OBJECT3134203d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2878.jpeg2025-05-13T09:20:42.000Z"b86586daab7690e5d9ae6caf305f1b46"CRC64NVMEFULL_OBJECT2330081d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2880.jpeg2025-05-15T09:38:06.000Z"21b869282bd0bf051b317adb83ffff4f"CRC64NVMEFULL_OBJECT2290017d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2881.jpeg2025-05-13T07:37:33.000Z"49c2c5a5ae917ebfa2cde4958219abb7"CRC64NVMEFULL_OBJECT2617770d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2882_Development and preclinical characterization of HER2×Trop-2 bispecific antibody-drug conjugates (bsADCs) with auristatin microtubule inhibitors_Chen.jpeg2025-05-15T09:12:20.000Z"2cc93e4c9ad57d1abcf27d7596866323"CRC64NVMEFULL_OBJECT2764973d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2883.jpeg2025-05-13T10:01:34.000Z"1af42ee5b608ec10f3a0daafcc0b9b2c"CRC64NVMEFULL_OBJECT3728628d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2884.jpeg2025-05-16T08:08:31.000Z"404a1b8e35337780424555080669c7cd"CRC64NVMEFULL_OBJECT2872541d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2885.jpeg2025-05-08T11:20:00.000Z"c1b82c9530f658b5f3d0988a17058837"CRC64NVMEFULL_OBJECT2629709d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2887_Next generation antibody drug conjugates targeting HER2 and TROP2 Multi-Payload ConjugatesTM targeting orthogonal mechanisms of cell killing_Kendall.jpeg2025-05-15T05:00:51.000Z"3f6453d193c5b113c455a6cad8d21913"CRC64NVMEFULL_OBJECT2791326d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2888.jpeg2025-05-13T10:53:10.000Z"15d7f6b03a161aa3bbc29fd010087921"CRC64NVMEFULL_OBJECT2727100d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2890.jpeg2025-05-13T08:25:24.000Z"54eb65ce216b3bd457dd774a21075ccd"CRC64NVMEFULL_OBJECT2694530d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2891_In vitro comparison of Kadcyla and Enhertu in breast cancer with varying HER2 expression proliferation, internalization, bystander effects and toxicity.jpg2025-05-26T13:46:09.000Z"836c409ba2ee4c85fbbad9d140c27c48"CRC64NVMEFULL_OBJECT2702942d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD28_Nivolumab_CRC_Andre.jpg2026-01-21T06:28:21.000Z"b31adaf8f221d94851b995e65f4f43c2"CRC64NVMEFULL_OBJECT1931072STANDARD29 sept 2025/2025-09-29T11:24:27.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0STANDARD29 sept 2025/Beijing Cancer Hospital.jpg2025-09-29T13:43:44.000Z"5688476e9ea5a22149cc74c5d9d87952"CRC64NVMEFULL_OBJECT7904d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29 sept 2025/Carisma.png2026-04-02T12:17:14.000Z"97b8c9c341cabaca845fea0ec5ebc1bc"CRC64NVMEFULL_OBJECT5542d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29 sept 2025/F-STAR.jpg2026-04-02T13:35:54.000Z"fe6e06474f26d3eea27dffd1f466e5a9"CRC64NVMEFULL_OBJECT6483d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29 sept 2025/HCW.png2026-04-02T13:41:03.000Z"2dcef9ddbdb908df556ff6ad68e069e1"CRC64NVMEFULL_OBJECT4003d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29 sept 2025/New Approaches to Brain Tumor Therapy Consortium.png2026-04-02T13:48:48.000Z"9c249df2a3ae2eee9f9bd1d076b87e96"CRC64NVMEFULL_OBJECT5582d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29 sept 2025/Northern Jiangsu People's Hospital.png2025-09-29T11:24:43.000Z"42af4f256f9110221077e145b6cdf5e6"CRC64NVMEFULL_OBJECT202163d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29 sept 2025/Philochem.png2026-04-02T13:42:23.000Z"c3291b6d0c9378a896a844cc2888d98f"CRC64NVMEFULL_OBJECT4565d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29 sept 2025/Qwixel Therapeutics.jpg2026-04-02T13:38:28.000Z"2ddc66d94f6a42347003bb9d5e9cd7dd"CRC64NVMEFULL_OBJECT10900d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29 sept 2025/Sarossa plc.png2026-04-02T12:30:35.000Z"aaf472fb0b3badafce350f73ca519c36"CRC64NVMEFULL_OBJECT8918d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29 sept 2025/Teva Pharmaceutical.png2026-04-02T13:39:35.000Z"a6a04dcce6e44afa77ab07a4add89a09"CRC64NVMEFULL_OBJECT4801d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29 sept 2025/The Affiliated Panyu Central Hospital, Guangzhou Medical University.png2025-09-29T11:51:58.000Z"92d3955b427018e67d07aa42e201ebf1"CRC64NVMEFULL_OBJECT10259d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29-04-2025/2025-04-29T14:26:46.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29-04-2025/Christian.jpg2026-01-15T10:35:54.000Z"8d4d79b345e34b3f181728375cf20195"CRC64NVMEFULL_OBJECT68414d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29-04-2025/Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma.docx2026-01-12T09:17:45.000Z"13f94801c95eda026bc76ffe7b9b72e0"CRC64NVMEFULL_OBJECT1480647d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29-04-2025/Kyinno Biotechnology.JPG2025-04-29T14:26:47.000Z"b4a98677b047fabc3cb344fad27be232"CRC64NVMEFULL_OBJECT54786d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29-04-2025/Phrontline Biopharma.JPG2025-04-29T14:26:47.000Z"0082443a7caacfb7ff3b5ea994515015"CRC64NVMEFULL_OBJECT40187d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29-04-2025/Shizuoka Cancer Center.jpg2026-01-15T06:12:14.000Z"7cb02a1b318b3811e2af61cd82d991fa"CRC64NVMEFULL_OBJECT46765d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29-04-2025/The First People’s Hospital of Lianyungang.jpg2026-01-15T08:02:07.000Z"f8b7a8630c172b230f1548585eeea1f5"CRC64NVMEFULL_OBJECT53392d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD291_SOX+Oxaliplatin+Anti-PD-1 + CAR-like T-cell_GGEJ Adenocarcinoma_Qin.pptx2026-01-20T08:41:21.000Z"33cedd1e749bfbb940b3b78a1cb67f86-4"CRC64NVMEFULL_OBJECT27282756d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2933.jpeg2025-05-13T06:16:01.000Z"04eb0b197a90a6a44d564b5460aeb26f"CRC64NVMEFULL_OBJECT2707712d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2936.jpeg2025-05-08T08:17:09.000Z"81032f3464be8ddbf7f5139bea6567d5"CRC64NVMEFULL_OBJECT2877975d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2940_Preclinical development of a next generation antibody drug conjugate (ADC) targeting CDH17 for treatment of solid tumors_Lian.jpeg2025-05-15T08:56:20.000Z"ba5063a33c89253a5c09e344de77a7f4"CRC64NVMEFULL_OBJECT2543013d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2943.jpeg2025-05-13T06:56:01.000Z"238f24f38364db04225ff826b51be10b"CRC64NVMEFULL_OBJECT1297668d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2945.jpeg2025-05-12T10:50:46.000Z"78fe3697e49051a9ecee147d7659415d"CRC64NVMEFULL_OBJECT3070263d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2953.jpeg2025-05-13T07:22:35.000Z"f53e9c2064dd4eb463f04e5ecf3f2f99"CRC64NVMEFULL_OBJECT3024054d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2954.jpeg2025-05-13T06:24:35.000Z"b8dba524c2cd635464a3ea78a6b09cf0"CRC64NVMEFULL_OBJECT2704648d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2955.jpeg2025-05-16T13:19:29.000Z"e7279c5925652b91bebe9673983fd835"CRC64NVMEFULL_OBJECT2609940d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2956_Anti-tumor activity of camptothecin analog conjugate of a RSPO4-based peptibody targeting LGR4 or 5 or 6 in preclinical models of colorectal cancer_Toh.jpeg2025-05-16T05:04:29.000Z"0ffba31758e893e4803350c243802d57"CRC64NVMEFULL_OBJECT3277914d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD296.jpeg2025-05-16T08:11:52.000Z"62ca8cd7397a502b737c42edac3fe109"CRC64NVMEFULL_OBJECT3262812d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2961_AZD9592 an EGFR_cMET bispecific antibody-drug conjugate (ADC) demonstrates target-dependent efficacy in colorectal cancer (CRC) patient-derived xenograft (PDX) models_Zheng.jpeg2025-05-23T10:37:26.000Z"98f1958ec2285ebd2e5907176989f408"CRC64NVMEFULL_OBJECT2511100d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2964.jpeg2025-05-22T13:44:30.000Z"5fea2b98bf9b34c224b11245b777e79b"CRC64NVMEFULL_OBJECT2230000d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2965.jpeg2025-05-19T17:06:10.000Z"06d6ec8d869091a5867e54a408044ca7"CRC64NVMEFULL_OBJECT2487790d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2966.jpeg2025-05-13T08:34:17.000Z"e46e247cd608213563a40c8f7e212f96"CRC64NVMEFULL_OBJECT2283836d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2968P_Atezolizumab_Mesothelioma_AtezoMeso_Pasello.pdf2025-10-31T14:24:37.000Z"f37738b19ae773c80e5ff39ef6ee06f9"CRC64NVMEFULL_OBJECT592876d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD297P ESMO ASIA 2025.pdf2026-01-08T10:47:54.000Z"9fdc4d346147e925aa9f9088272e3aa3"CRC64NVMEFULL_OBJECT332683d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD297P.pdf2026-01-08T10:45:42.000Z"9fdc4d346147e925aa9f9088272e3aa3"CRC64NVMEFULL_OBJECT332683d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD298P_SHR-1701_GEJ_SHR-1701 Plus CAPOX in Patients with Advanced Gastric_Zhi Peng.pdf2025-12-17T13:52:34.000Z"a644f37fa530327e048809e2b3aefa36"CRC64NVMEFULL_OBJECT246895d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD2990P_Adebrelimab_Thyroid cancer_Kou.pdf2025-11-06T07:46:20.000Z"da946f5af59ddbfe4a7ebe74f8b6dbc9"CRC64NVMEFULL_OBJECT3690761d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD29_The utilization of patient-derived organoids as a platform for drug screening Chemotherapy, targeted therapy, and immunotherapy_Park.jpg2025-05-07T11:22:35.000Z"0a2b19e79dcb27719b63c728f3b1cf50"CRC64NVMEFULL_OBJECT3401882d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD30 sept 2024/2024-09-30T09:16:18.000Z"d41d8cd98f00b204e9800998ecf8427e"0d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD30 sept 2024/Shanghai Children's Medical Center.jpg2024-09-30T09:17:13.000Z"6283a4193d7b036e0f8b822687431701"116300d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD30 sept 2024/The University of Texas Health Science Center at Houston.jpg2024-09-30T09:17:14.000Z"286c15686cb32a8b06e0d1f69121470c"61355d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD30 sept 2024/Washington D.C. Veterans Affairs Medical Center.jpg2024-09-30T09:27:56.000Z"eb9b57fa3656e88c86b3f0798e1ebe1e"212272d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3000_DB-1310_UCLA Health Cancer Care_advanced solid tumors_Ph1_2_DB-1310, a HER3-targeted_Lisberg.pdf2025-07-22T06:50:53.000Z"120bcb25cc2f76e0c75baf0ea6577f9d-3"CRC64NVMEFULL_OBJECT17208075d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3001_iza-bren (BL-B01D1)_Department of Medical Oncology_Small Cell Lung Cancer_Ph1_Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug __Zhang.pdf2025-06-13T04:38:55.000Z"a4fee4d8aebede27594fc39c5fb49970-3"CRC64NVMEFULL_OBJECT17993348d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3001_iza-bren (BL-B01D1)_Department of Medical Oncology_Small Cell Lung Cancer_Ph1_Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug __Zhang.zip2025-06-12T15:13:36.000Z"c9969cc0075df334ed6721c65cbbfe55"CRC64NVMEFULL_OBJECT7875834d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3002_iza-bren (BL-B01D1)_Department of Medical Oncology_Small cell lung cancer_Ph1_Phase I study of iza-bren_Zhang.pdf2025-06-12T13:15:38.000Z"71fb75c98a5eb417718f342e1cfd0b9d"CRC64NVMEFULL_OBJECT3669014d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3010_Sigvotatug vedotin_Dana-Farber Cancer Institute_NSCLC and HNSCC_Ph1_SGNB6A-001_Clinical Results_Sehgal.pdf2025-06-13T11:51:17.000Z"84711311298a20ba9135b604d2316cac-2"CRC64NVMEFULL_OBJECT13537967d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3024_BAT8008, a TROP_2 antibody_drug conjugate_Zhao.jpeg2025-06-13T11:51:09.000Z"fd49dc65796ef7ac2171d9c9c400657e"CRC64NVMEFULL_OBJECT2946211d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3027_Telisotuzumab vedotin_University of Colorado Cancer Center_NSNSCLC_Association of genomic alterations in circulating tumor DNA (ctDNA) with clinical response to telisotuzumab vedotin_Camidge.jpeg2025-06-12T14:32:06.000Z"d796f607fd15dbcd8469753ff8a44670"CRC64NVMEFULL_OBJECT4206141d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3039_Rinatabart sesutecan_Genmab_Endometrial cancer_Phase I_II_GTC118401_Rinatabart sesutecan for patients with cohort B2 of the GTC118401 study_Winer.jpeg2025-06-13T12:31:12.000Z"c8db1bac1564e26f6358380bc9a866e7"CRC64NVMEFULL_OBJECT3108627d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3041_ZL_1310.jpeg2025-06-16T07:51:00.000Z"56ff76b9ce5c68a1d42ef4d169384558"CRC64NVMEFULL_OBJECT4064636d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3073P_Nectin4_Enfortumab Vedotin + Pembro_lamUC_Exploratory Analysis EV302_Mar.pdf2025-10-24T10:59:06.000Z"295427ee9ae10105f4f4684892dc3db1"CRC64NVMEFULL_OBJECT378695d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3074P_Nectin4_Enfortumab Vedotin_lamUC_EV 103 Cohort K_Friedlander.pdf2025-10-27T09:34:42.000Z"fbe329096a97e0aa28621fc0cbc5bae0"CRC64NVMEFULL_OBJECT329621d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3079P_HER2_Disitamab Vedotin + BCG_Bladder cancer_Results from Formula-01_Tan.jpg2025-10-23T18:23:24.000Z"c1e24523292b307bc8f6b89c5c890dd8"CRC64NVMEFULL_OBJECT5003204d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3083P_Trop-2 PD-L1_Avelumab+Sacituzumab govitecan_urothelial cancer_JAVELIN_Valderrama.pdf2025-10-24T08:18:31.000Z"fbd5cd8050a2ff5ae2874cbd35f57796"CRC64NVMEFULL_OBJECT820042d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3105_Unveiling the potential of humanized bispecific antibody a novel approach to tumor suppression in oncology_Jablonska.jpeg2025-05-16T07:21:33.000Z"ad77c6ce4dc10c2b6186771ae8b87bf9"CRC64NVMEFULL_OBJECT2580198d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD311.jpeg2025-05-16T13:07:18.000Z"89e753960961ff9b48e298ed3eb549e5"CRC64NVMEFULL_OBJECT2866318d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3114eP_Toripalimab_MIBC_Yudong Cao.pdf2025-11-06T07:58:23.000Z"117d92f42b4d7eaa1f3b64638ad1cc6d"CRC64NVMEFULL_OBJECT609135d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3123_A first-in-human phase I Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors STAMINA-01_Hayat.jpeg2025-06-20T12:23:15.000Z"a2d3c1e0804b0972d58eee12e51f1f98"CRC64NVMEFULL_OBJECT3359281d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3132.jpeg2025-05-13T08:52:22.000Z"687473543904832b7d5e1eed176a0a13"CRC64NVMEFULL_OBJECT3006483d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3133_PF-08046032_Pfizer_Carosino.jpg2025-05-28T14:35:02.000Z"4af3c1f6747fd9ff87da718f1a3882fa"CRC64NVMEFULL_OBJECT2979317d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3133_PF-08046032_Pfizer_Carosino.png2025-05-28T14:24:51.000Z"c4d6d324ae35140168ab02254c3c9f26"CRC64NVMEFULL_OBJECT3595938d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3140.jpeg2025-05-16T12:18:21.000Z"aad21f72472e7e8885cb9e4181c45707"CRC64NVMEFULL_OBJECT2403400d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD316_Translational studies of HDM2012, a novel topoisomerase inhibitor ADC targeting MUC17, in patient derived GC, CRC, PDAC tumor models_Xia.jpeg2025-05-23T07:41:37.000Z"fa0d6daa61d8be3c4c170b3300863cf0"CRC64NVMEFULL_OBJECT2483676d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD323_Preclinical evaluation of SDV2102, a novel PSMA-targeting DAR1 ADC for mCRPC treatment_Kolodych.jpeg2025-05-07T12:03:28.000Z"261312bb9764071688154b2555b303c9"CRC64NVMEFULL_OBJECT2817910d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3296_AZD4512, A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies_Han.png2025-12-18T09:53:03.000Z"1b92cb6d939f0ce2e8a3c56c1cd052f5"CRC64NVMEFULL_OBJECT1359885d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD329_Molecular and functional determinants of response to venetoclax and inotuzumab ozogamicin in CD22-positive ALL_Murakami.pdf2025-12-19T13:27:20.000Z"82f12d5898172461284c2d8881f4bc53"CRC64NVMEFULL_OBJECT2047656d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3307_Polatuzumab vedotin induced activation of B-cell receptor signaling creates a synthetic lethality with BTK_Havranek.png2025-12-18T10:06:30.000Z"a8a204c446a312a4e42f68734227bc53"CRC64NVMEFULL_OBJECT1830709d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3352_Pembrolizumab_B-ALL_High efficacy of blinatumomab combined with pembrolizumab_Sandhu.png2025-12-19T09:28:43.000Z"cea6c5417c731c90f349aa2e7a0d1ead"CRC64NVMEFULL_OBJECT1997696d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3358_Safety and efficacy of low-intensity chemotherapy combined with sequential blinatumomab and inotuzumab ozogamicin immunotherapy_Liu.png2025-12-18T11:21:20.000Z"03faf5e519f4b73d98a81d11361d6427"CRC64NVMEFULL_OBJECT1329968d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD340.jpeg2025-05-16T09:08:41.000Z"ad7740b0a685352a479a4eb9cfc47157"CRC64NVMEFULL_OBJECT3119243d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD341.jpeg2025-05-16T12:58:41.000Z"2a26668f61a6c054afae82a2d33173ab"CRC64NVMEFULL_OBJECT2874306d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3411_Transcriptional modulations of tumor microenvironment by BH3120, a PD-L1x4-1BB bispecific antibody_Jiangcheng Xu.jpg2025-05-14T14:08:26.000Z"af3150787fde54537db87bbe612329bf"CRC64NVMEFULL_OBJECT3474255d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3417.jpeg2025-05-19T17:27:43.000Z"90867857c9fb6eb4ffd3d6e292aec514"CRC64NVMEFULL_OBJECT2371525d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3422_Pivekimab sunirinine (PVEK) combined with FLAG-IDA for medically fit adults with untreated_Appelbaum.png2025-12-19T13:29:36.000Z"7cf477c2b7d24e36e361284f584e3b5f"CRC64NVMEFULL_OBJECT1218406d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD343.png2025-07-15T16:07:33.000Z"a1d772b648b8431e84d85d5ce1525658"CRC64NVMEFULL_OBJECT3669721d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD343_GenSci143, a novel B7-H3×PSMA bispecific and potential best-in-class ADC, for the treatment of metastatic castration-resistant prostate cancer_Fu li.jpeg2025-05-16T09:07:25.000Z"2642027211de18c326610362c9f8a6f7"CRC64NVMEFULL_OBJECT2761883d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD344.jpeg2025-05-16T09:08:38.000Z"d6ad76654deb2f8abc72671328f1d0b8"CRC64NVMEFULL_OBJECT3192517d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD345.jpeg2025-05-16T11:38:14.000Z"ae1d896102408b60c7701576d462007a"CRC64NVMEFULL_OBJECT2808468d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD347.jpeg2025-05-19T17:08:07.000Z"244b325100087c6870d4f7ea95598a4e"CRC64NVMEFULL_OBJECT3381029d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD348.jpeg2025-05-19T17:06:39.000Z"4efd25b3e2af73b9155b430464b6f7a8"CRC64NVMEFULL_OBJECT2234054d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD349.jpeg2025-05-19T17:36:35.000Z"b90b45dc9bc2f72217e9f440fef01baf"CRC64NVMEFULL_OBJECT2751044d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3536.jpeg2025-06-09T05:51:46.000Z"645dcd75b321deebbfcc607a78f1527b"CRC64NVMEFULL_OBJECT3774015d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD355_Early analysis of activity in esophageal cancer during phase 1 dose escalation of IKS014_Ameratunga.jpg2026-01-12T07:35:25.000Z"6dfd84590c47421c3de7961ebcdc8d95"CRC64NVMEFULL_OBJECT1812103d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD360P_Cadonilimab_HCC_Cadonilimab Plus Lenvatinib (LEN) and hepatic arterial infusion chemotherapy (HAIC)_CCGLC-011_Gao.pdf2025-12-17T14:04:35.000Z"76b3acd9d8f30bf5bf01c50e49f60007"CRC64NVMEFULL_OBJECT4990323d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD362.jpg2026-03-10T21:54:35.000Z"e67f8a806323cd45d977b893468e5d05"CRC64NVMEFULL_OBJECT1763602d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD364_A multicenter, randomized phase 2 study evaluating the efficacy and safety of HLX43_Wang.jpg2026-01-12T08:15:41.000Z"8a59ec9d5fb6a445b8812b638283983f"CRC64NVMEFULL_OBJECT1981640d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD364_HLX43_ESCC_Wang.jpg2026-01-20T10:24:26.000Z"8a59ec9d5fb6a445b8812b638283983f"CRC64NVMEFULL_OBJECT1981640d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3681_Phase 2 study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH)_Allan.png2025-12-18T13:03:38.000Z"f79a96883d38aaee303cec7cddfd710d"CRC64NVMEFULL_OBJECT1140428d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3682_Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma, high efficacy and tolerability_Yang.png2025-12-19T09:51:46.000Z"dc634ea51c594d2c951fba7f9dbffdfd"CRC64NVMEFULL_OBJECT1304330STANDARD3735_Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy_Kamdar.png2025-12-19T11:56:52.000Z"4001772e8437043458ae32f4300f1e10"CRC64NVMEFULL_OBJECT1614753d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3745_Phase 2,3 trial of zilovertamab vedotin plus standard of care in relapsed,refractory diffuse large B-cell lymphoma_Armand.png2025-12-19T12:47:57.000Z"becf27825b1956d0ccc6c4f08b9a0f16"CRC64NVMEFULL_OBJECT1061193d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD377_ Tisle combined with POFI_ G GEJ adenocarcinoma_SYLT 023_Liyu Su.jpg2026-01-20T10:38:23.000Z"3695372e44e2097cbbc03744c85de22d"CRC64NVMEFULL_OBJECT2166800d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD378_Tislelizumab_GC_Bassam.jpg2026-01-21T12:27:25.000Z"2c051d3c7367becbd4bceb102b9a080d"CRC64NVMEFULL_OBJECT1668495d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD381_ TIS comine with chemotherapy vs placebo Combine with CT_ESCC_ RATIONALE 306_Harry H Yoon.jpg2026-01-21T10:06:02.000Z"4c1037a4ea1873f39420711b6f094507"CRC64NVMEFULL_OBJECT1860479d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD382.jpeg2025-05-16T13:04:08.000Z"a8debf64a39243d7033398cf204c0a0e"CRC64NVMEFULL_OBJECT3319634d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD382_Efficacy and safety of disitamab vedotin (RC48) in combination with sintilimab_Liu.jpg2026-01-12T09:24:59.000Z"c2e3241f4c73add876f91d62c5fe2395"CRC64NVMEFULL_OBJECT2504214d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD395_Sintilimab_GC_Jin.jpg2026-01-20T11:21:53.000Z"976592ea1b52bd51416aa847cc64bda8"CRC64NVMEFULL_OBJECT1558542d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3B Pharmaceuticals.jpg2025-11-25T13:50:59.000Z"4405dfe373a77d30e7ea0b963a486b33"CRC64NVMEFULL_OBJECT40041d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD3BP Pharmaceutical Pipeline.jpg2025-11-26T13:04:05.000Z"b299f982ab134d2f61c2b879300ba134"CRC64NVMEFULL_OBJECT110197d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/2025-08-04T08:49:22.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT0STANDARD4 AUG 2025/Academy of Military Medical Sciences.jpg2025-08-12T10:07:30.000Z"c35d82da988a01b25a7fb139f21986ae"CRC64NVMEFULL_OBJECT82086d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Bradmer Pharmaceuticals.avif2025-08-22T08:41:57.000Z"62be14b13fb0129076830fc44484bed6"CRC64NVMEFULL_OBJECT2710d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Cancer Institute and Hospital, Chinese Academy of Medical Sciences.jpg2025-08-26T10:00:18.000Z"9a0ead286cee5d9a1538830eff522ada"CRC64NVMEFULL_OBJECT265205d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Citius pharma.jpg2025-08-19T11:02:55.000Z"32d5aec0c4b7cf621369f0c62c0c8a98"CRC64NVMEFULL_OBJECT12113d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Emory_Medical_School_logo.png2025-08-04T08:49:49.000Z"e8fb11f737f53c6da985f357f877c971"CRC64NVMEFULL_OBJECT22504d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Endocyte.png2025-08-19T12:50:39.000Z"9c601e96fc0c8c42b2306d1867aa0c96"CRC64NVMEFULL_OBJECT5905d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Hebei Medical University Fourth Hospital.png2025-08-26T09:21:22.000Z"cbad3b20c34df7d5226475da55c1c724"CRC64NVMEFULL_OBJECT11074d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Institut Curie.png2025-08-20T11:52:21.000Z"1ff20f20fb65288f80c0f4f357a652f6"CRC64NVMEFULL_OBJECT31182d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/KCR S.A..png2025-08-20T09:01:58.000Z"2e382c4ae70fd066c12a0f617fa7e78b"CRC64NVMEFULL_OBJECT7352d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Lund University.png2025-08-04T08:49:39.000Z"417fbca3febaf6cc92b8699d11f8c23b"CRC64NVMEFULL_OBJECT5665d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Lund University.png.jpg2025-08-04T08:51:08.000Z"75d91c9151d3e640857900ccf8a77b91"CRC64NVMEFULL_OBJECT123909d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Mashhad University of Medical Sciences.jpg2025-08-12T13:07:33.000Z"9eab57498e4a9640284c14ef9da83c70"CRC64NVMEFULL_OBJECT56520d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Nectin 4.png2025-08-22T11:26:52.000Z"5704f53f3b0203f6bfa0f6321151c6cd"CRC64NVMEFULL_OBJECT62295d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Pharma olam.png2025-08-20T08:58:27.000Z"96ef5b48f972feca676a224b27de0e8d"CRC64NVMEFULL_OBJECT10864d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Saarland University.png2025-08-04T08:49:49.000Z"500e2b887670c2efe2ecbd1a1257e89b"CRC64NVMEFULL_OBJECT60657d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Screenshot 2025-08-21 184635.png2025-08-21T13:17:44.000Z"706be81ffe1496d26e89291b1db4cf06"CRC64NVMEFULL_OBJECT66153d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Screenshot 2025-08-22 153537.png2025-08-22T10:06:00.000Z"63416d241eddbab663b1c94957489ebf"CRC64NVMEFULL_OBJECT97117d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Theradex.png2025-08-20T09:23:04.000Z"406b8767ddd9f42d21f4c522d190017c"CRC64NVMEFULL_OBJECT6111d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/University of Shizuoka.jpg2025-08-12T11:16:19.000Z"528ddbb9fc3025b7ef2a61d7b9898b08"CRC64NVMEFULL_OBJECT64959d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/VVH-7.jpg2025-08-21T12:24:02.000Z"adc5221dad19579e47630b7b39ade941"CRC64NVMEFULL_OBJECT21114d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Xiamen Cancer Hospital.jpg2025-08-12T10:46:29.000Z"b2e4c3fc0a75c2b26852a0957a29c0b0"CRC64NVMEFULL_OBJECT45035d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/Zhengzhou University.jpg2025-08-12T11:36:20.000Z"680d2cc9cd3c62c83fa4e854ca8e3cda"CRC64NVMEFULL_OBJECT68848d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/bradv.jpg2025-08-22T08:44:22.000Z"7c5be399e233da8baf1dba5b4961fb62"CRC64NVMEFULL_OBJECT46437d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4 AUG 2025/huazhong university of science and technology.jpg2025-08-13T06:47:08.000Z"485ea4dad69c3fc22fae784b32991ea3"CRC64NVMEFULL_OBJECT112116d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4017_IBI343_Fudan University Shanghai Cancer Center_PDAC_Ph1_Clinical Results_Yu.pdf2025-06-12T09:24:48.000Z"0a05ce66ff63f5b484ea064c848ba0cd-2"CRC64NVMEFULL_OBJECT10948600d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD402P.pdf2026-01-15T10:03:03.000Z"76d8f191b9386983216b92b339540891"CRC64NVMEFULL_OBJECT624330d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4031_Intensive chemotherapy combined with Serplulimab Trastuzumab in patients with advanced HER2 positive gastric cancer_Liu.jpg2025-06-13T06:24:09.000Z"53c530a22ddc7673072aee784a717d61"CRC64NVMEFULL_OBJECT1933952d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4038_Hematologist based management of, ineligible for ASCT who received belantamab mafodotin plus lenalidomide,dexamethasone_Terpos.png2025-12-18T12:02:23.000Z"f57ea80ec3c2e2a1b9a190ac4ac0356d"CRC64NVMEFULL_OBJECT1515672d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4042_Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for REP Home advanced esophageal squamous cell carcinoma (ESCC) a single-arm, phase Il clinical trial_Gu.jpeg2025-07-15T06:06:45.000Z"660f4303297565ca8ea14719802450bf"CRC64NVMEFULL_OBJECT2555014d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4060_Belantamab mafodotin, nirogacestat, and pomalidomide in patients with relapsed,refractory multiple myeloma_Hultcrantz.png2025-12-18T12:38:04.000Z"584095b1b2e6ee8afd2e7a0fa505d216"CRC64NVMEFULL_OBJECT1108037d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4069_Neoadjuvant Toripalimab Plus _Zhao.jpeg2025-06-15T04:07:15.000Z"3125454b80a66207f8c5825e557e16e8"CRC64NVMEFULL_OBJECT3348139d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4093_SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC) a phase 1b_2 study_Liu.jpeg2025-06-04T06:54:27.000Z"1640bcae66854cc7084e280cca8a8ed8"CRC64NVMEFULL_OBJECT2970605d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4098_Li.jpg2025-06-13T06:22:01.000Z"324dfe0ae3f8f7a26ce8bf0a518a0a24"CRC64NVMEFULL_OBJECT5246296d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD410_Adebrelimab combine with Paclitaxelcombine with Nedaplatin_Neoadj ESCC_Phase II_Jianqun Ma.jpg2026-01-21T10:38:39.000Z"6845d3499559662cf161d38354fedb9f"CRC64NVMEFULL_OBJECT1679109d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4157.jpeg2025-06-06T06:13:43.000Z"916ed1926c1d0d38fb0fc8db49b2c7d2"CRC64NVMEFULL_OBJECT3305444d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4157_Efficacy and Safety of Surufatinib Plus KN046 and Chemotherapy in First Line Advanced Pancreatic Cancer A Single-arm, Phase 1b-2 Trial_Wang.jpeg2025-06-26T06:48:47.000Z"916ed1926c1d0d38fb0fc8db49b2c7d2"CRC64NVMEFULL_OBJECT3305444d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD41598_2025_22669_MOESM1_ESM (1).pdf2025-11-06T11:53:52.000Z"479770eb9d7d4755086d5c756b193ada"CRC64NVMEFULL_OBJECT374638d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD416_Ipi_Nivo_mRCC_Cytoreductive stereotactic hypofractionated RT_Ipi Nivo_CYTOSHRINK_Lalani.pdf2026-03-06T11:29:42.000Z"193a99c7ec88f4f8fc331127d15de34d"CRC64NVMEFULL_OBJECT3099070d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD418_Periop Chemo combine with Atezolizumab combine with Tiragolumab_ECGEJ_Phase I II_Blum Murphy.jpg2026-01-20T11:48:05.000Z"08a3d6e18fc55da352d56209ccbf433e"CRC64NVMEFULL_OBJECT2227635d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD420_Durvalumab and tremelimumab in the RAMPART trial_renal cell carcinoma_Merrick.pptx2026-03-13T10:23:56.000Z"c85516917da7b8d95a839b222d6908ed"CRC64NVMEFULL_OBJECT4299091d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD422_Fruquintinib+serplulimab non-clear cell renal cell carcinoma.pptx2026-03-13T09:44:29.000Z"829bdbe4ac7b940dec97a7fcafdfb0e5-2"CRC64NVMEFULL_OBJECT9600545d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4253.jpeg2025-05-13T08:00:53.000Z"b3b3bc201cd1c003cb122e2e96f590d3"CRC64NVMEFULL_OBJECT3161450d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4256.jpeg2025-05-15T08:19:19.000Z"a52b7d3372d66533fe12ae9f68a8487b"CRC64NVMEFULL_OBJECT2917554d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD425eP_Tislelizumab_ESCC_Neoadjuvant chemoradiotherapy (nCRT) followed by sequential tislelizumab for resectable esophageal_CRIS_Jiang (2).pdf2025-12-18T07:29:35.000Z"64be86a589e86d020c32b0b43155d264"CRC64NVMEFULL_OBJECT264004d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4266.jpeg2025-05-08T11:12:18.000Z"c383b326b93a6a78117f030918e0add2"CRC64NVMEFULL_OBJECT2269726d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4270.jpeg2025-05-13T09:09:21.000Z"cb4cff6518445015574be6bd39897f97"CRC64NVMEFULL_OBJECT3300786d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4328.jpeg2025-05-19T17:33:47.000Z"c9421d40ab66860c92f44e257b1c0e4a"CRC64NVMEFULL_OBJECT2201171d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4356.jpeg2025-05-15T08:45:26.000Z"9a929d6a5312803367d2066f3c6b2d2f"CRC64NVMEFULL_OBJECT3040584d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4423.jpg2025-12-22T12:00:00.000Z"ad0d5bc6f3444086d9c5f56be06724f6"CRC64NVMEFULL_OBJECT109371d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4426.jpg2025-12-22T12:34:13.000Z"855bc759f79b53890a17e59a96e47fcd"CRC64NVMEFULL_OBJECT110320d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4501_Avelumab + sacituzumab govitecan (SG) vs avelumab_The Sidney Kimmel Comprehensive Cancer Center_advanced urothelial carcinoma_Ph2_JAVELIN_ Avelumab + sacituzumab govitecan vs avelumab monotherapy_Censits.pdf2025-06-13T05:26:01.000Z"732ba846c2f4149204bd6fa38d69fb1b-2"CRC64NVMEFULL_OBJECT15602999d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4518_First results of SURE-02 A phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients witt.pdf2025-06-12T06:13:50.000Z"2ff578f499d6b44e0c9611999fbb85ef-2"CRC64NVMEFULL_OBJECT14650729d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4526_Anlotinib combined with sintilimab 1l treatment in patients with advanced nccRR Preliminary results from an exploratory_Dong.jpeg2025-06-20T09:52:11.000Z"12248fb7a10ee2379bf0b05f1d7c16b8"CRC64NVMEFULL_OBJECT3014612d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4561_Avelumab maintenance therapy in UC in Japan Subgroup analyses by best overall response PBC in a post-marketing surveillance (PMS) population_Kikuchi.jpeg2025-06-20T10:31:42.000Z"b0d4c6afe7576139b90220caa62c0ff7"CRC64NVMEFULL_OBJECT4672459d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4569.jpeg2025-05-08T07:40:43.000Z"1f33fd251f331181a3f1c17a23be517a"CRC64NVMEFULL_OBJECT2049155d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4583_ enfortumab vedotin (EV)_University of California_muscle invasive bladder cancer_Ph1_2_ EV_103 cohort H_Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin_Mar.jpeg2025-06-19T11:31:45.000Z"08af500e5ff427b5239e57e7c871b3e0"CRC64NVMEFULL_OBJECT3910924d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4591_First survival outcomes and biomarker results of SURE_01_Neoadjuvant sacituzumab govitecan (SG) monotherapy_Maiorano.jpeg2025-06-11T08:16:45.000Z"40651c743e1afea69a7e0be0c2b722ab"CRC64NVMEFULL_OBJECT637125d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4723_Development and preclinical activity of BSI-721, a novel antibody-drug conjugate (ADC) targeting cadherin 17 (CDH17) in gastrointestinal cancers_Hao.jpeg2025-05-15T04:44:40.000Z"520d1c0afa5a6f9849a38723cb179f6f"CRC64NVMEFULL_OBJECT2395087d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD473P_anti-PD1-antibody_TNBC_Jiaxuan Liu.pdf2025-11-05T12:24:04.000Z"accf06b0085218197583d51e67f2085b"CRC64NVMEFULL_OBJECT855910d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4746.jpeg2025-05-15T07:20:51.000Z"afb003da0875bdd8dbacee2134884d64"CRC64NVMEFULL_OBJECT2457471d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4751.jpeg2025-05-08T10:01:33.000Z"9d9c4472d031d0436ea2b5181fddc136"CRC64NVMEFULL_OBJECT3016782d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4772_AI-guided engineering and preclinical development of biparatopic anti-DLL3 antibody-drug conjugates (ADCs)_Chen.jpeg2025-05-13T12:27:29.000Z"30c9ead79431666d3dda485f39a7b242"CRC64NVMEFULL_OBJECT2098026d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4773.jpeg2025-05-15T09:28:33.000Z"0e1d9ab29f303a4ed6f51b050a9064ec"CRC64NVMEFULL_OBJECT3177109d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4776_Preclinical study of bispecific antibody drug conjugates (bsADCs) targeting DLL3 and SEZ6 demonstrated potent anti-tumor activity in small cell lung cancer (SCLC) xenograft models_Zang.jpeg2025-05-13T11:22:40.000Z"31e63c1657c0a3987b2374aef09b418c"CRC64NVMEFULL_OBJECT2387574d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4778.jpeg2025-05-13T09:56:33.000Z"b0a9b7ece41e4369c9b7b582ce1dc9ec"CRC64NVMEFULL_OBJECT2666806d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4779_Preclinical studies of BB-1705 An EGFR-targeting eribulin-containing ADC with an affinity optimized antibody to minimize potential toxicities to normal tissues_Xia.jpeg2025-05-23T11:53:30.000Z"fa5b2d1fa8d0a0784c6e4426d4718201"CRC64NVMEFULL_OBJECT2885901d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD477_ pembro_ HC_ keynote 937_Stephen.pptx2026-01-20T07:41:40.000Z"aaf0ef4583671af796b44fa6b99a274f"CRC64NVMEFULL_OBJECT891857d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4783.jpeg2025-05-16T13:40:12.000Z"7890514f75829010438e1aca9412274a"CRC64NVMEFULL_OBJECT2536196d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4784.jpeg2025-05-15T07:47:23.000Z"37278899d20c63564746f996c12efccf"CRC64NVMEFULL_OBJECT2750713d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4784_ADCE-D01 a first in class antibody drug conjugate against urokinase plasminogen activator receptor-associated protein (uPARAP).jpg2025-05-26T13:53:11.000Z"37278899d20c63564746f996c12efccf"CRC64NVMEFULL_OBJECT2750713d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4793_BCG033 a first-in-class PTK7×TROP2 bispecific ADC demonstrating potent and broad efficacy in various preclinical models_Ma.jpeg2025-05-13T10:22:46.000Z"480997dc0cb08f8987d44595d3bcf3bc"CRC64NVMEFULL_OBJECT2648388d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD4823.jpeg2025-05-15T10:31:19.000Z"f02e3997fdae6924ebeae74680d71d18"CRC64NVMEFULL_OBJECT3159725d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD492.jpg2026-03-06T10:34:49.000Z"1c0cc27e7d12d84468a2fe5a2a134ec9"CRC64NVMEFULL_OBJECT1959593d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5-year survival outcomes after perioperative pembro patients with HPV-unrelated LA-HNSCC) A multi-center two-cohort phase 2 trial_Sim.jpeg2025-06-10T05:20:31.000Z"da6765d0fc76cf298f8412a049f7d52f"CRC64NVMEFULL_OBJECT4060187d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5015_DB‑1311_Macquarie University_Prostate cancer_Ph1b2_Parsonson.pdf2025-06-24T07:52:46.000Z"a1b21956d1ce1413caba76b7aa7c5e3d-2"CRC64NVMEFULL_OBJECT14101451d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD502_MAGIC D_ biliary tract cancer receiving durvalumab and chemotherapy_Chi Lin Hsieh.jpg2026-01-21T07:04:19.000Z"7d4fb66ab36c2d2117bae36c619037cd"CRC64NVMEFULL_OBJECT1430862d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD503_CBM588 + Nivo + Ipi_mRCC_Dose escalation of CBM588 with Nivo_Ipi_NA_Zugman.jpg2026-03-09T11:49:29.000Z"2b599528219dcf2f2a3ee7b47ee78393"CRC64NVMEFULL_OBJECT1993419d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5051_MHB088C_Beijing Cancer Hospital_CRPC_Ph I and Ph II_Clinical results_Shen.jpeg2025-07-08T07:40:11.000Z"93dca4b237edb2039f77b7d68b190686"CRC64NVMEFULL_OBJECT3185201d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5052_CD123-targeted radiotheranostics of Acute Myeloid Leukemia with 89Zr 177Lu-labeled pivekimab_Zhao.png2025-12-18T11:14:16.000Z"c9e7c1a8dc11a9ab924db7f72a365994"CRC64NVMEFULL_OBJECT1273087d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5057.jpeg2025-06-09T05:52:41.000Z"c4c8e7612f37fb416be759cf21cda912"CRC64NVMEFULL_OBJECT3569924d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5057_A biomarker-selected phase II study of durvalumab and tremelilumab in patients with previously treated metastatic castration-resistant prostate cancer resistant to AR pathway inhibitor_Hotte.jpeg2025-07-15T06:08:18.000Z"c4c8e7612f37fb416be759cf21cda912"CRC64NVMEFULL_OBJECT3569924d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD505_KEYMAKERU03_CCRC.jpg2026-03-16T04:50:26.000Z"facb4491a52e9ae06eb8516f2223e767"CRC64NVMEFULL_OBJECT1674892d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD506.jpg2026-03-06T08:44:50.000Z"6931f90bffdd9fb86c4e8147b262725b"CRC64NVMEFULL_OBJECT2307231d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5064_Optimal dosing of vobramitamab duocarmazine, a CD276 (B7-H3) antibody-drug conjugate_Kirkey.png2025-12-18T12:27:18.000Z"ebb0c974f342c42851d05841a6ebd73a"CRC64NVMEFULL_OBJECT1776728d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD508_Cabo + Nivo_aRCC_Depth & durability of response with Cabo+Nivo_CheckMate 9ER_Suárez.jpg2026-03-16T04:55:59.000Z"640e3b2175fadcd9dc2b9c0587ef09d5"CRC64NVMEFULL_OBJECT1960265d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD508_First-in-human phase I trial combining radiopharmaceutical therapyusing a 90y-anti-CD25_Wong.pdf2025-12-19T09:57:06.000Z"d70e93777336c4c10c98d6206ac9cba5"CRC64NVMEFULL_OBJECT1204838d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5131_Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin_Goulart.png2025-12-19T11:34:45.000Z"48f475930fa41f1dc6db8df0816159c2"CRC64NVMEFULL_OBJECT1032025d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD513_Cabo_Nivo_RCC_Cytoreductive surgery_Cabo_Nivo_Runcie.jpg2026-03-09T11:24:03.000Z"07c58739c4ed7eca5f59bfc36e7cf872"CRC64NVMEFULL_OBJECT2193991d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5195_Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic_Pemmaraju.png2025-12-18T11:20:04.000Z"6b5552d77f074d6bfa59678312bb69f2"CRC64NVMEFULL_OBJECT1227272d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5203_Final results of a first-in-human Phase I study of INA03, a novel CD71-TfR1-targeted ADC_GARCIAZ.png2025-12-19T09:55:31.000Z"c62ab961c7a320a7ee6a9dae18ff7d1f"CRC64NVMEFULL_OBJECT977514d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5216_Phase 1,1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin_Chan.png2025-12-18T11:55:05.000Z"dc9dd51d2729bc2f30a5b525db399b58"CRC64NVMEFULL_OBJECT1066500d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD52eP_Integrin β6_PF-08052667_Bladder cancer_ADC optimized for intravesical delivery_Dekker.jpg2025-10-22T13:20:21.000Z"22662bd7439ec8afc29a08b7bf6faddf"CRC64NVMEFULL_OBJECT5797152d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5364_Long-term results of the FIL-FLAZ12 Phase III randomized trial_Tavarozzi.png2025-12-18T14:56:40.000Z"e6efe9f922a694f9a7e2a19475e51444"CRC64NVMEFULL_OBJECT1085390d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD536MO_HER2_SHR-A1811 + pertuzumab_mBC_Phase 1b2_Huang.pdf2025-10-27T07:16:51.000Z"a58086ebc5b08f73be2153ee58da56d4"CRC64NVMEFULL_OBJECT4063768d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD538_TATE+Nivolumab_IO-Refractory HCC_Phase II_Nadine Abi-Jaoudeh.jpg2026-01-20T10:45:57.000Z"8628bdcc58497394e08780a1063b62b5"CRC64NVMEFULL_OBJECT2512606d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5410_Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P_Peterson.png2025-12-18T10:27:13.000Z"75be327bc883fe170ca37322cbf86cd4"CRC64NVMEFULL_OBJECT1114874d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5417_Pembrolizumab_Lymphoma_Final results from the embolden trial pembrolizumab_EMBOLDEN_Nathan Roberts.png2025-12-19T10:19:44.000Z"d3be7712d12c1d2fa05b867455f14bca"CRC64NVMEFULL_OBJECT1412801d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD542MO_Tislelizumab_UC_Efficacy and safety of disitamab vedotin (DV) combined with tislelizumab_Cheng.pdf2025-12-17T11:19:56.000Z"74404d955180813558b5fb7c2d28ec04"CRC64NVMEFULL_OBJECT435680d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD544.pdf2026-03-10T22:09:51.000Z"bae06845a5bbe8306ab12c63539a0f22"CRC64NVMEFULL_OBJECT389171d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5447.jpeg2025-05-26T12:13:16.000Z"55ab756bce036da2f46b8aaff0173c58"CRC64NVMEFULL_OBJECT2206653d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5449.jpeg2025-05-15T10:05:20.000Z"45340808598c9519401acad455d3c6da"CRC64NVMEFULL_OBJECT2468236d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5450.jpeg2025-05-13T10:08:48.000Z"2f8957bab4b053e6050cf857f85a8c84"CRC64NVMEFULL_OBJECT3078651d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5450_JSKN022, a first in class multi-specific ADC targeting PD-L1 and ITGB6 8 with an innovative DNA topoisomerase I inhibitor demonstrates encouraging efficacy in preclinical models_Ting Xu.jpeg2025-05-16T09:01:30.000Z"2f8957bab4b053e6050cf857f85a8c84"CRC64NVMEFULL_OBJECT3078651d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5451.jpeg2025-05-16T11:49:41.000Z"00be47f184300542ea9d7cd417febd17"CRC64NVMEFULL_OBJECT2591014d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5452_Novel tryptophan-based antibody-drug conjugate (ADC) targeting EGFR-positive lung cancer demonstrates robust antitumor efficacy by triggering immunogenic cell death_Inoue.jpeg2025-05-12T12:38:32.000Z"4373ed0ad1c9d5e7507c1ec68478b72a"CRC64NVMEFULL_OBJECT2984094d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5453.jpeg2025-05-15T10:19:20.000Z"430551388a8180e127a0d5b940b925eb"CRC64NVMEFULL_OBJECT1696777d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5454.jpeg2025-05-08T11:46:26.000Z"146fc6ce23ad97422739c1aedd286ef8"CRC64NVMEFULL_OBJECT2367330d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5455.jpeg2025-05-08T08:05:50.000Z"a61bb110443ba2647388eae111a50f31"CRC64NVMEFULL_OBJECT2384816d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5460_C6P, a claudin 6 (CLDN6) directed ADC containing pyrolobenzodiazepine (PBD) for the treatment of advanced solid tumors_Zhang.jpeg2025-05-09T05:21:41.000Z"599369c92e000a8e7673274b2e301a9f"CRC64NVMEFULL_OBJECT2235900d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5461_Sintilimab_Lymphoma_Orelabrutinib, sintilimab_Xianggui Yuan.png2025-12-19T11:02:48.000Z"4f059eb480c701424304e1b97af313e4"CRC64NVMEFULL_OBJECT1304372d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5462.jpeg2025-05-13T10:52:15.000Z"0d2190278484b1c3d4e3e63e588daafb"CRC64NVMEFULL_OBJECT2729510d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5463.jpeg2025-05-08T07:39:04.000Z"7539760cd21fa2e149e822e9f7c9a5ec"CRC64NVMEFULL_OBJECT2977983d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5466_7MW4911, a novel cadherin 17-targeting ADC, demonstrates potent efficacy in preclinical models of gastrointestinal cancers_Xun Gui.jpeg2025-05-09T04:20:01.000Z"0d5334d5462b5e58d89828f048171eb9"CRC64NVMEFULL_OBJECT2498468d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5467.jpeg2025-05-15T10:35:03.000Z"afbf963410fadc67247d5dcf08717c5c"CRC64NVMEFULL_OBJECT2718782d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5469.jpeg2025-05-16T08:50:09.000Z"91c3abf79635a452199fbf2c7ca4be47"CRC64NVMEFULL_OBJECT3341412d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5469_Preclinical safety and efficacy of SOT109, an antibody-drug conjugate targeting cadherin 17 (CDH17) for the treatment of colorectal and other gastrointestinal tract tumors_Jensen-Smith.jpeg2025-05-16T08:50:31.000Z"325080cbb5528be6b5c5864d3192164c"CRC64NVMEFULL_OBJECT3348022d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5477_Polatuzumab vedotin combined with orelabrutinib and rituximab (PRO Regimen)_Shi.png2025-12-19T10:34:32.000Z"3597428012010af6be4086452473f83a"CRC64NVMEFULL_OBJECT1227396d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5485_Consolidation with loncastuximab tesirine for large B-cell lymphoma patients_Hamilton.png2025-12-18T10:56:02.000Z"94beb5123f1fe7fc8afb90ffb6501b58"CRC64NVMEFULL_OBJECT1151498d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD549P_HER2_ARX788 + Toripalimab_aBC and Solid tumor_Phase I study_Wang.jpg2025-10-22T11:47:16.000Z"df524bdf2037c9aee912bc8afdd81b5c"CRC64NVMEFULL_OBJECT4180875d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD549_Donafenib combine with Sintilimab TACE_uHCC_DosinTACE_Xiaoyun Hu.jpg2026-01-20T11:02:42.000Z"8630a4991f16a8f22e69cbb7f8d78c61"CRC64NVMEFULL_OBJECT1513107d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5510_Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients_Gritti.png2025-12-19T12:22:34.000Z"36350e60f200719d9d0523fd709fc518"CRC64NVMEFULL_OBJECT1620382d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD555MO_TROP2_Dato-DXd + durva_amTNBC_BEGONIA study Result_Schmid.pdf2025-10-27T06:07:10.000Z"4685e81bc962386c1e2377fd801b8290"CRC64NVMEFULL_OBJECT2673974d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5563_Circulating tumor DNA (ctDNA) monitoring in participants (pts) with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) ± MK-4830_Lee.jpg2025-06-13T10:03:40.000Z"86372ae69689fedb9a413a6ba13f88fe"CRC64NVMEFULL_OBJECT6138632d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5564_Disitamab vedotin_Peking University Cancer Hospital & Institute_OC_Ph II_Preliminary analysis_Shu (1).jpeg2025-06-19T06:17:26.000Z"7182380f8b0baeb32e1c0164ef3fa8a8"CRC64NVMEFULL_OBJECT3007131d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD558.jpeg2025-05-16T07:15:22.000Z"e737b6204b8a626ab128406cdee4df88"CRC64NVMEFULL_OBJECT2935995d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD558_Ivosidenib+Durvalumab + GemCis_IDH1+ CCA_Ph1b2_Do-Youn Oh.pptx2026-01-20T12:10:31.000Z"38bc48b7966497aa6c55a8239c5c30d0"CRC64NVMEFULL_OBJECT423426d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5597_Efficacy of novel urokinase plasminogen activator receptor-associated protein targeted antibody-drug conjugates in patient-derived xenografts of soft tissue sarcoma_Wang.jpeg2025-05-08T11:25:44.000Z"99dff3a662b334ad802df0e51a421cdb"CRC64NVMEFULL_OBJECT2398866d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD560_Avelumab_Axitinib_aRCC_Avelumab_Axitinib_Sunitinib_aRCC_JAVELIN Renal 101_Venugopal.jpg2026-03-06T12:06:53.000Z"227de094782271304a486b174b7b083a"CRC64NVMEFULL_OBJECT1711771d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD560_SBRT+Atezolizumab+Bevacizumab_aHCC_Phase I_Timothy Brown.jpg2026-01-20T12:19:58.000Z"5f17b54bd263c46bb77f5550153c6c73"CRC64NVMEFULL_OBJECT3065045d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD564_Sintilimab_HCC_Fang.jpg2026-01-20T12:36:01.000Z"03d1ea92d6c7bb94f8cf80ba6ccc017c"CRC64NVMEFULL_OBJECT2106036d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD565.jpg2026-02-03T04:41:45.000Z"2d60bc310f7f97fa26066c1743318902"CRC64NVMEFULL_OBJECT45248d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD565_HAIC or Lenvatinib+Sintilimab_Neoadj HCC_Phase II_Yunlong Cui.jpg2026-01-20T13:34:12.000Z"9e321c016c43c77793f06c4ae04e0a4f"CRC64NVMEFULL_OBJECT1982077d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5675.png2025-05-16T08:00:42.000Z"9f3f2d73f1c1feb5508dc308cba1cc2e"CRC64NVMEFULL_OBJECT2738483d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5703_Zip-code drug conjugates (ZDCs)_Mizrachi.png2025-12-18T12:05:23.000Z"49753a3ba19cf6a3529ae1da3bcb7f80"CRC64NVMEFULL_OBJECT1582018d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD571P_Adebrelimab_TNBC_Tao Wang.pdf2025-11-05T12:45:38.000Z"0e8c48faa4082003287700d93f704ace"CRC64NVMEFULL_OBJECT214324d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD5730.jpeg2025-05-08T10:17:11.000Z"49c42365bddbb2b7c54db8bf882504bf"CRC64NVMEFULL_OBJECT3140723d92d196cdfa4e7d4f90f06aacaaa91103455ac31c30eb951c9ac57d27f234caeSTANDARD